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Dry powder inhalation formulations typically involve the co-processing of an 
active pharmaceutical ingredient and a relatively coarse excipient, commonly 
known as carrier particles, to ensure accurate dose metering, increased 
device clearance and the dispersion of the respirable particulates upon 
device actuation.
It is well recognised that there is a critical relationship between the surface 
characteristics of the carrier particles and the overall delivery performance of 
a DPI formulation. Such variations in the physicochemical properties of the 
carrier particles have a direct influence on the de-aggregation behaviour of 
respirable drug particles, and typically lead to considerable batch-to-batch 
variations. These uncontrolled modifications threaten the overall efficiency 
and reproducibility of the inhalation therapy. The uncontrollable nature of the 
surface properties of commercial grade a-lactose monohydrate is a 
consequence of the rigorous industrial processing techniques utilised in the 
preparation of the excipient particles. To overcome these issues, a novel 
temperature controlled surface etching process has been developed in this 
study to controllably modify the physicochemical properties of commercial 
lactose particles. In vitro aerosolisation behaviour of surface etched lactose 
was investigated using salbutamol sulphate as a model drug. Significant 
difference (p<0.05) in the fine particle delivery of the drug was measured 
upon decreasing the surface roughness of lactose carrier particles. The study 
further highlighted that the aerosolisation efficiency was highly dependent on 
the degree of surface etching suggesting the importance and the need to
control and optimise the degree of surface roughness of carrier particles for 
DPI formulations.
Further work focussed on studying the potential of the surface etched 
lactose, produced by the temperature controlled surface etching process, as 
a carrier of choice for inhalation systems aimed for low dose drug delivery. 
The study indicated that the surface smoothing of lactose particles resulted in 
a significant increase in the aerosolisation performance at lower drug 
concentrations (minimum FPF at drug load of 63.5 pg for surface etched 
lactose compared to a drug load of 135 pg for commercial grade lactose), as 
a consequence of considerably reducing the presence of the so-called ‘active 
sites’.
Of equal importance to modifying the surface properties of excipient particles 
for improved aerosolisation performance, is the physicochemical stability of 
the formulation upon storage at elevated temperature and relative humidity 
conditions. In vitro aerosolisation behaviour of the controlled surface etched 
lactose and commercial grade lactose formulations was investigated as a 
function of storage for one and three months at 25°C, 75% RH and one 
month at 40°C, 75%RH. No significant difference in the delivery performance 
was observed for the surface etched lactose formulation before and after 
storage. Accelerated stability testing and in vitro investigations of commercial 
and secondary processed lactose indicated that controlled surface etched 
lactose maintained drug deposition efficiency with respect to commercial, 
untreated lactose based formulations at elevated conditions of humidity and 
temperature.
This study emphasised on the importance of utilising a secondary post­
treatment procedure to the bulk crystallisation process of excipient particles 
for DPI formulations. Improved inter and intra physicochemical characteristics 
of excipient particles may significantly enhance the uniformity and 
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1.8).
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SEM Scanning electron microscopy
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Va total mass of gas
V|_ volume of saturated solution
Vm mass of gas in monolayer
Wa work of adhesion
Wc work of cohesion
XRPD X-ray powder diffraction
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The majority of pharmaceutical formulations are primarily designed to deliver 
therapeutic medicaments in a solid dosage form preparation via a number of 
routes which can be classified with the following categories: oral, rectal and 
parenteral routes. The latter includes intravenous, intramuscular and 
subcutaneous drug delivery of injections which may contain a suspension of 
solid drug particulates (Byrn, 1982). It is only recently, however, that the 
respiratory system has been genuinely regarded as a potential port of entry 
for delivery of therapeutic agents to the systemic circulation (Wall, 1995; 
Johnson, 1997; Mobley and Hochhaus, 2001). Drug delivery to the 
respiratory tract has become a well recognised and increasingly effective 
route for providing therapy to a variety of pulmonary disorders (Hickey et al.,
1994). Bronchodilators, steroids, mast cell stabilisers and anti-cholinergic 
drugs are examples of pharmacologically active ingredients that provide 
therapeutic treatment for a number of respiratory illnesses such as asthma, 
chronic obstructive pulmonary disease (COPD), bronchitis and cystic fibrosis 
(Pritchard, 2001).
Inhalation therapy has been shown to exhibit significant advantages in 
comparison to other routes. These include rapid onset of action due to local 
delivery of active ingredients to the bronchi and bronchioles. Furthermore,
1
lung drug delivery allows the administration of relatively low doses of the 
active pharmaceutical ingredient having equivalent therapeutic efficacy to 
solid dosage formulations, while minimising possible side effects associated 
with the oral route (Timsina etal., 1994). For systemic drugs, the rapid 
absorption via the respiratory bronchioles and alveoli circumvents the 
degradation of the drug via hepatic first pass metabolism as associated with 
the oral route (Byron and Patton, 1994; Wall, 1995).
The human lung is the organ responsible for the exchange of gaseous 
substances between the atmosphere and the blood capillaries of the 
circulatory system. The structural and functional features of the peripheral 
regions of the lung provide a tremendous surface area of about 100 m2for 
gaseous exchange. Together with the rich supply of blood, the alveoli and 
terminal bronchioles provide unique characteristics for rapid drug absorption 
and, thus, high bioavailability (Byron and Patton, 1994; Patton, 1996).
The leading airway into the lung is the trachea which continually bifurcates 
into a series of bronchi and bronchioles. These areas are described as the 
conducting airways. The peripheral regions of the lung are associated with 
the respiratory bronchioles and alveoli which are the basic structure 
responsible for the blood capillary gas exchange (Patton, 1996). A schematic 













Figure 1.1. Description of the structure of the human lung.
The delivery of a therapeutic aerosol dose to the respiratory tract is currently 
possible via three systems: pressurised metered-dose inhaler (pMDI), dry 
powder inhaler (DPI) and a nebuliser (Borgstrom and Newman, 1993; Clark, 
1995a; Pitcairn etal., 1995; Concessio etal., 1997; Pitcairn etal., 2000). The 
characteristic physicochemical properties of the formulations and the 
engineering of these inhalation devices have been shown to greatly influence 
the efficiency and therapeutic efficacy of inhalation therapy (de Boer et al., 
1995; Steckel and Muller, 1997a; Srichana etal., 1998a; Zeng etal., 2002a; 
Zeng etal., 2002b; Labiris and Dolovich, 2003).
Until very recently, the mainline treatment for inhalation therapy was via 
pressurised MDI delivery systems, which typically consisted of an active 
pharmaceutical ingredient suspended in a suitable chlorofluorocarbon (CFC) 
propellant system. However, its long term future has been put into question 
due to several disadvantages (Timsina etal., 1994). These include the 
deleterious effects on the ozone layer and related global warming issues 
arising from the use of CFCs, inter-patient variability resulting from poor
3
actuation-inspiration co-ordination and certain limitations surrounding the 
metering system within a pMDI, which limits the delivered dose to 1 mg 
(Ganderton and Kassem, 1992). Furthermore, the relatively high velocity of 
the delivered droplets often results in considerable drug loss due to impaction 
in the oropharynx (Brambilla etal., 1999). In an attempt to overcome the 
drawbacks associated with the use of the environmentally harmful CFCs in 
pMDI systems, alternative non-CFC propellants were developed. These are 
the hydrofluoroalkanes (HFAs). However, such conversion from CFCs to 
HFAs was found to be problematic to some extent due to variations in their 
physicochemical properties, such as polarity, vapour pressure and density 
(Crowder etal., 2001). Moreover, although less than CFCs, HFAs were also 
found to contribute to global warming.
Nebulisers do not utilise volatile propellants. With the use of a compressor, a 
liquid aerosol of drug is nebulised as a mist. Nebulisers are more commonly 
utilised in a hospital setting for patients suffering from severe respiratory 
distress requiring high doses of medicament. Their lack of portability, high 
cost and low therapeutic efficacy has limited their wider use (Horsley, 1988).
To overcome some of the issues relating to the use of pMDIs and nebulisers, 
the introduction of dry powder inhaler (DPI) device in the 1970s has offered 
several advantages over the other systems (Bell etal., 1971). In a dry 
powder inhaler formulation, the drug is delivered as a powder without the 
need of a propellant, avoiding the related environmental concerns 
encountered with pressurised metered dose inhalers (pMDIs). Dry powder 
inhaler devices are portable and are automatically breath actuated, which 
removes the requirement of the need to synchronise actuation of the device 
with the inhalation manoeuvre of the patient (Timsina etal., 1994; Ashurst et 
a!., 2000).
To deliver the therapeutic dose to either the conducting or peripheral regions 
of the respiratory tract, the active pharmaceutical ingredients need to be 
formulated in the optimum particle size range for efficient delivery (Lord and 
Staniforth, 1996). For treatment of respiratory diseases, such as asthma and
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COPD, the active ingredients need to be delivered to the smooth muscles of 
the conducting airways. These require the formation of particles in the size 
range of 2-7 pm. For systemic delivery, however, particles need to be 
delivered in the 0.5-2 pm size range (Hinds, 1999). Efficient delivery to 
peripheral conducting airways is markedly influenced by the physicochemical 
properties of the aerosol particles together with certain physiological 
considerations that ought to be encountered. For example, in part of the 
structural design of the respiratory tract, the oropharynx exhibits a 90° bend 
which efficiently collects air-suspended particulates via impaction (Li and 
Edwards, 1997). Furthermore, inhaled particles have to circumvent a tortuous 
path that is a resultant of concomitant branching and narrowing of the 
airways. Equally important is also the mucociliary clearance mechanisms and 
high atmospheric humidity that may potentially inhibit inhaled particles from 
reaching peripheral regions of the lung (Malcolmson and Embleton, 1998). 
Thus, both the site and the mechanism of deposition of drug particulates in 
the lung can be to some extent influenced by the particle size of air 
suspended particulates.
In an attempt to meet these stringent requirements, the active drug in a DPI 
formulation needs to be micronised within a critical particle size range. This 
high-energy process usually leads to highly cohesive powders and poor 
flowability. To increase flowability and aid in the metering and deaggregation 
of the therapeutic dose, the micronised powder is typically blended with 
coarse carrier particles (Staniforth, 1980; Ganderton, 1992). The carrier 
particles tend to be of sufficient size to allow adequate fluidisation of the 
formulation out of the device. These particles subsequently, deposit in the 
oropharynx. Upon actuation of a dry powder inhaler device, the forced 
inspiration breath of the patient provides sufficient energy to both fluidise the 
drug-carrier blend and to dissociate and disperse drug from the surface of the 
carrier particles (Kulvanich and Stewart, 1987; Ganderton, 1992; French et 
al., 1996).
The deposition of these re-dispersed particles within the respiratory tract 
occurs through various mechanisms. For larger particulates (>10 pm), the
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main mechanism responsible for deposition in the mouth, throat and upper 
airways is via inertial impaction. Deposition within the conducting airways is 
dominated by gravitational sedimentation due to the decreased velocity and 
larger relaxation times for the inhaled particles in the lower bronchi and 
bronchioles. Peripheral and alveoli deposition is influenced by diffusion and 
gravitational sedimentation, and is usually exhibited by particles with a 
diameter in the size range of 0.5 - 2 pm. Particles exhibiting a diameter of 
less than 0.5 pm are most likely to be exhaled, due to their low mass which 
limits the influence of gravitational forces and the limited period for diffusion 
within the peripheral regions of the lung (Malcolmson and Embleton, 1998). 
Other possible deposition mechanisms include interception and electrostatic 
attraction (Hinds, 1999).
Considering the critical importance of particle size on the delivery efficiency 
of a therapeutic dose, respirable sized particles are defined in terms of their 
aerodynamic diameter. Since the majority of aerosol particles are irregular in 
shape, with considerable variations in size and density, the influence of their 
physical properties on aerosolisation behaviour can be accounted for by 
determining the aerodynamic behaviour of the particles rather than their 
geometric shapes and sizes. The aerodynamic diameter is defined as the 
diameter of the spherical particle with a density of 1 g/cm3 that has the same 
settling velocity as the particle being investigated (Hinds, 1999).
Over the last two decades, great prominence has been directed towards the 
research and development of a strategic and structural design for both 
formulation and device, which would yield efficient and reproducible drug 
delivery via the respiratory tract. However, despite the characteristic 
properties of the formulation and/or design of the inhalation device, the 
performance is principally related to the shear forces and turbulent behaviour 
of the airflow generated from an optimised inspiratory action by the patient 
(Ziskind etal., 1995). The potential of achieving optimum dispersion and 
deposition is therefore governed by the co-interaction of a number of key 
determinants (Concessio etal., 1999; Chew etal., 2000; Clarke etal., 2000), 
most notably the patient inspiratory manoeuvre. The inspiration technique
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critically relies on the synergy between the engineered DPI device and the 
inspiratory energy created by the patient through the device (Ganderton and 
Kassem, 1992; Clark, 1995a; Hindle and Byron, 1995; Srichana etal., 
1998a).
In spite of the striking advances that have been accomplished lately in the 
development of pharmaceutical powder formulations, certain aspects related 
to the upholding of an optimum therapeutic dose delivered to target sites are 
yet to be embarked upon. Concurrent investigations are being undertaken to 
further elucidate the rather ambiguous fundamental behaviour of particulate 
interactions and the role they may exert upon powder behaviour during 
processing, handling, fluidisation and aerosolisation of formulations.
1.2 Inter-particulate interactions
The importance of inter-particulate interactions in pharmaceutical solid 
dosage forms cannot be underestimated. Inter-particulate forces influence 
many bulk properties of powders. These include flowability, mixing, de­
aggregation, dispersion, compression and even drug dissolution (Staniforth 
etal., 1981; Staniforth and Rees, 1982; Staniforth, 1994; Podczeck, 1998a; 
Clarke etal., 2002).
Particle-particle interactions, with the exception of covalent bonds, occur as a 
result of long-range physical attractive forces. A covalent bond, is defined as 
the chemical bond resulting from the attractive forces existing between atoms 
in a molecule. Such covalent forces are extremely strong exhibiting a typical 
energy of formation in the range of 300 to 700 kJ.mol'1. Particle interactions, 
on the other hand, are due to significantly weaker physical bonding, usually 
exhibiting energies of bonding of less than 40 kJ.mol'1. Although these forces 
are much weaker than chemical bonds, their influence however, extends over 
greater distances, thus, termed as “ long-range forces” .
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Particulate interactions can be broadly differentiated into two main classes, 
depending on the nature of the two interacting materials. These are namely 
cohesion and adhesion. Cohesion refers to the interactive forces that exist 
between particles of the same material, while adhesion refers to the 
interactive forces that exist between particles of different materials. A powder 
is said to be adhesive when the component particles tend to readily adhere to 
the surface of an object of larger dimensions. That is to say, the magnitude of 
the interaction forces applying between the particle and the surface exceed 
the magnitude of the separation forces exerted on the particle itself.
However, such interactions only exist if one of the interacting parties exhibits 
a particle dimension of less than 10 pm (Visser, 1995), where gravitational 
forces play a negligible role in the behaviour of particles with respect to the 
physical forces.
1.2.1 Forces contributing to particle-particle interactions
Particulate interactions dominating the behaviour of a powder system are 
governed by a number of interacting forces. These interactive forces are a 
resultant of the integrated influence of the omni-present van der Waals 
forces, the dynamic electrostatic (Coulombic) force and capillary force 
(Visser, 1989).
The extent of such forces is strongly subjective to the influence of various key 
elements which mainly include particle physical properties such as particle 
size, shape and surface texture (Podczeck, 1998a; Walz and Sun, 2002) and 
the surrounding environmental conditions such as temperature and RH 
(Coelho and Harnby, 1978). The dynamic electrostatic forces, for example, 
arise from the contact and separation of two different contiguous surfaces 
during powder handling. Such surfaces may become charged as a result of 
triboelectrification (Carter etal., 1992; Byron etal., 1997). On the other hand, 
capillary forces dominate particulate interactions due to the increased risk of 
the presence of a physisorbed water layer with increasing levels of relative
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humidity (%RH) (Price etal., 2000; Price etal., 2002a). A further phyico- 
mechanical force which needs to be taken into account in DPI based 
interactions, especially when dealing with irregularly shaped pharmaceutical 
solids exhibiting rough surfaces, is mechanical interlocking. Mechanical 
interlocking between particles occurs when particles interlock as they come 
into contact, and may be a significant contributor to the overall particulate 
interactions (Zeng etal., 2001a). A more detailed overview of each of these 
physical forces is described below.
1.2.1.1 Van der Waals forces
The van der Waals forces are electrodynamic forces which are ubiquitous 
between all interacting materials. They are extremely strong at short range, 
and retard rapidly with separation distance (Visser, 1995). The van der Waals 
forces are a composite of the following types of forces:
Keesom-orientation van der Waals forces
A Keesom orientated force is induced when two molecules, which both 
exhibit dipole moments, orientate themselves so that the positive pole of one 
is directed towards the negative pole of the other (permanent moment / 
permanent moment interactions).
Debye-induction van der Waals forces
A Debye induction force arises when a molecule which has a dipole moment, 
induces an electrical dipole in a neighbouring apolar molecule, provided that 
the latter is polarizable (permanent moment / induced moment interactions).
Dispersive van der Waals forces
Also known as van der Waals-London forces, the dispersive van der Waals 
force is induced by the random movement of electrons within an electron 
cloud, with respect to their nuclear protons. The formation of a temporary 
dipole and the integration of these instantaneous moments will create an
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electrical field, which in turn will induce a dipole to the neighbouring neutral 
molecules by polarization (instantaneous moment / induced moment 
interactions).
The adhesive van der Waals force (Fvdw) between a spherical particle and a 
plane surface in vacuum for example, may be expressed by the following 
equation:
Equation 1.1
where of is the diameter of a particle that is separated by a distance rfrom a 
plane surface, and A is Hamaker’s constant which represents the interaction 
energy that is dependent on the molecular properties of both interacting 
materials such as the number of atoms per unit volume of particles, the 
frequency of the interacting electronic oscillators and the polarisability of 
molecules.
The van der Waals force (Fvcjw) between two ideally smooth spherical 
particles exhibiting diameters c/* and d2, separated by a distance rin vacuum 
can be expressed by the following equation:
Equation 1.2
As seen from both equations, the separation distance rof interacting 
surfaces is a critical parameter. With the influence of the separation distance 
being the square power in the denominator, suggests that the magnitude of 
van der Waals forces will significantly decrease as the separation distance 
increases. Moreover, indicating the possibility for manipulating of van der 
Waals forces by the presence of large asperities that would maintain a 




Electrostatic forces may result from the contact and separation of two 
different contiguous surfaces exhibiting different energy states. The 
electrostatic charge induced is termed as the process of triboelectrification, 
and is often used to describe the process of a surface gaining an electrical 
charge due to contact, sliding or friction with another surface. These charges 
can either arise from the contact of an uncharged particle with a charged 
particle, or the contact of two uncharged particles that have different work 
functions. The processing of pharmaceutical powders, such as high sheer 
mixing, sieving or micronisation will most likely induce triboelectrification of 
particulate surfaces (Carter etal., 1992; Staniforth, 1994; Byron etal., 1997). 
The simplest form of electrostatic force occurs when two charged particles 
come into contact, they will be subjected to either attraction or repulsion 
depending on their electrical charge signs. The magnitude of the electrostatic 
force (Fe/) between them could be simply described by applying Coulomb’s 
law:
Equation 1.3
where q-\ and q2 are the electrical charges on the two particles respectively, e 
is the permittivity and d is the distance of separation.
Another form of electrostatic forces occurs when a particle with either a 
positive or negative charge q encounters an uncharged particle of radius r, 
the first particle will induce what is called an image charge on the second 
particle. The electrostatic force (Fc) between these two particles can be 
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where d is the distance between the charged and uncharged particles.
When the uncharged particle is a flat earthed conducting surface (r-+°°), the 





Finally, when two uncharged solids come together and are separated by a 
small distance, an electrostatic force may be induced upon contact, provided 
that they exhibit different work functions. Electrons from the material with the 
lower work function will be transferred to the material with the higher one, 
until eventually equilibrium is reached (Visser, 1989; Visser, 1995). In this 




Fw  =  7Z£r-
where AU  is the potential difference arising from the difference in work 
functions, ris the radius of the interactive particles and dis the distance of 
separation.
Indeed, electrostatic forces were found to exert significant implications on the 
behaviour of pharmaceutical powders (Staniforth, 1994; Mackin etal., 1997; 
Price etal., 2000; Rowley, 2001). Pharmaceutical ingredients (both active
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and excipients), are generally insulators. The low conductivity of these 
materials effectively limits surface charges from dissipating into the particle 
core, and thus play a critical role in particulate interactions. If present, 
electrostatic forces between drug and excipient particles in a powder system 
are of crucial importance during the initial blending of the powder 
formulations. Furthermore, a study carried out by Staniforth and Rees 
indicated that electrostatic charges created by surface interactions between 
particles played an imperative role in maintaining the stability of the ordered 
mixes. Interestingly, ordered mixes that were subjected to some degree of 
triboelectrification were less prone to blend segregation compared to 
uncharged powders. Furthermore, triboelectrified blends exhibited reduction 
of the error limits between powder samples, which is of practical significance 
when considering the dosage content uniformity of pharmaceutical powder 
systems (Staniforth and Rees, 1982).
1.2.1.3 Capillary forces
Moisture tends to adsorb to a wide variety of polar materials, leading to the 
formation of hydrogen bonds. The adsorption, however, is highly dependant 
on the partial water vapour pressure (relative humidity) of the surrounding 
atmosphere and the hydrophilic/hydrophobic nature of the surface of the 
material. Condensation of water vapour onto surfaces may occur over a wide 
range of relative humidities, however it is considerably increased at higher 
levels of relative humidity. If the condensation of the water vapour is 
significant, the formation of a liquid bridge may arise between two contacting 
surfaces due to capillary interaction, leading the formation of a meniscus 
force (Coelho and Harnby, 1978; Schubert, 1984).
For two smooth spherical particles with radius rthat are wetted by a liquid 
with a surface tension of y and a contact angle a as diagrammatically 
represented in Figure 1.2, the force due to the formation of a liquid bridge 
can be expressed by the following equation:
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Equation 1.7
F  = hryr cos a
Figure 1.2. Diagrammatic representation of liquid bridging between two 
spherical particles.
In a similar manner, if water vapour condenses on the interface between a 
particle and a surface Figure 1.3, the meniscus thereby formed will 
correspond to the capillary force that will be added to the already present 
interaction forces, such capillary force is described by the following 
expression:
Equation 1.8
F = 2^7r(cos a  + cos p)
where a and p are the contact angles of the liquid with the surface and 
particle respectively as shown in Figure 1.3.
14
Figure 1.3. Diagrammatic representation of liquid bridging between a particle 
and a surface.
1.2.1.4 Mechanical interlocking
Although not a force, another type of particulate interaction which becomes 
more significant when the surfaces of the interacting particles are rough on a 
micrometer scale is mechanical interlocking. Mechanical interlocking is a 
mechanism which increasingly needs to be taken into consideration in 
regards to pharmaceutical powders, since processed powders usually exhibit 
a high degree of surface roughness. If such particles come into contact with 
one another, the surface asperities of the different interacting particles may 
mechanically interlock with one another. Furthermore, the contact area 
between these asperities will only constitute a relatively small fraction of the 
total surface area of the particle. Since the interactive force will be 
concentrated over a small surface area, the load exerted on these contact 
points will lead to an extremely high pressure over the contact areas. The 
pressure developed at these contacts may exceed the yield value of the 
material allowing it to flow. The flow will create a more exposed area for 
contact. This in turn will provide means of increasing the distribution of the 
load, until the applied force is insufficient to cause the particle to further yield 
(Cheng etal., 2002; Cheng etal., 2003).
Mechanical interlocking is even more critical if interacting particles possessed 
markedly variable dimensions. For example, if respirable sized drug particles
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are adhered to coarse carrier particles, whose surface asperities are larger 
than the diameter of the drug particles, this may lead to the formation of 
stronger inter-particulate bonds due to the entrapment of the fine drug 
particles within the surface clefts and indentations of the coarse carrier 
particle. Such an interaction is considered to be more significant than the 
interactive forces induced by the van der Waals, electrostatic and capillary 
forces for non-mechanically interlocked particulate interactions (Mullins etal., 
1992; Podczeck, 1996; Zeng etal., 2001a).
Theoretically, it is clear that particle interactions are a result of various 
mechanisms which contribute to particle adhesion. It is, however, rather 
onerous to quantify the dominant force, since many factors are involved in 
such interactions.
1.2.2 Factors influencing inter-particulate interactions
In light of the fact that inter-particulate interactions are indeed ruled by a 
number of mechanisms, several studies have outlined some of the major 
factors which may influence the cohesion/adhesion characteristics of 
respirable sized particles (Staniforth etal., 1982). These mainly relate to the 
physicochemical properties of interactive particles, such as particle size, 
particle shape, surface texture, electrostatic propensity and moisture sorption 
properties (Ganderton and Kassem, 1992; Podczeck, 1997; Podczeck, 1999; 
Chew etal., 2000; Zeng etal., 2001a; Chew and Chan, 2002). Inter­
particulate forces within the powder formulation have also been shown to be 
affected by the morphological properties of the drug and carrier particles 
(Kawashima etal., 1998b; Kawashima etal., 1998c; Louey etal., 2003), 
presence of ternary components (Tee etal., 2001; Louey etal., 2002), drug- 
carrier ratio (Steckel and Muller, 1997b), blending process (Staniforth, 1987; 
Zeng etal., 1996a) and environmental conditions during processing and 
storage (Young and Price, 2004). Further information regarding some of the 
main specific influences on particulate interactions are highlighted below.
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1.2.2.1 Particle size
It is apparent that the larger the particle the stronger the influence it will have 
on adjacent objects. For example, van der Waals forces are directly 
proportional to the radius of the particle (Lam and Newton, 1992). The 
specific influence of particle size on interaction forces has been investigated 
by Podczeck etal. (Podczeck etal., 1994; Podczeck etal., 1995). The 
performance of a powder is usually determined by the relative influence of 
inter-particulate forces in comparison to the gravitational forces acting upon 
the mass of the particle. The powder behaviour will, therefore, be directly 
affected with particle size, particularly when the dimensions of a particle are 
reduced to such an extent where particulate interactions become more 
significant than the gravitational influence which acts as separation forces on 
particles. Although dependant on physicochemical properties of a specific 
material, this transition from the macroscopic influences to the microscopic 
generally occurs for particles smaller than 60 pm (Kassem etal., 1989; 
Podczeck, 1998b; Zeng etal., 1999). Thus, the cohesive and adhesive 
properties of particles with a diameter less than 10 pm are governed by the 
van der Waals forces (dominated by the London dispersive forces) and the 
relative influence of the dynamic capillary and electrostatic forces. These 
physical forces govern why fine powders are intrinsically cohesive and, thus, 
exhibit poor flow properties (Ganderton and Kassem, 1992) and their 
propensity to adhere to solid surfaces (Lord and Staniforth, 1996; Staniforth, 
1996b).
1.2.2.2 Particle shape
In powder technology, it is almost always the case that the methods utilised 
in the production of particles give rise to particles with various geometrical 
properties. Thus, the resulting particle shape is considered as one of the 
most unreliable and uncontrollable factors which may influence inter­
particulate interactions. An increase in the separation distance between
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particles will directly result in a decrease in inter-particulate forces 
(Podczeck, 1998a). Whether particles exhibit a regular shape or not, the 
contact area between interacting surfaces and the tendency of particles to 
orientate themselves to the most stable conformation upon the application of 
an external energy play a significant role in controlling the adhesive 
properties of powders (Podczeck, 1996; Staniforth, 1996b).
1.2.2.3 Surface energy
The surface energy of a solid is defined as the free energy change during the 
increase of the surface area by one unit in vacuo. The excess energy is due 
to force imbalances rising at the surface of the material. Although a solid is 
rigid and resistant to stress, in a similar manner to the surface tension of a 
liquid, it possesses a surface energy resulting from the net imbalance of 
surface forces. The difference between a liquid surface and a solid surface, is 
that the molecules on the surface of a liquid move more freely than those on 
the surface of a solid, therefore, a consistent surface energy is omnipresent 
over the entire surface of the liquid, which is numerically equal to the surface 
tension of the liquid. Due to the considerable rigidity and reduced mobility of 
surface molecules of a solid, surface energy is unequally distributed over the 
solid surface. Regions such as edges and surface asperities may possess a 
higher energy than regions of plane surfaces. The level of variation in surface 
energy of a solid is highly dependent on the processing and treatment 
procedures which the material was subjected to such as crystallisation, 
milling, dissolution or condensation (Buckton etal., 1988; Ohta and Buckton, 
2004).
In general, solids exhibiting high surface energy are more likely to form 
strong inter-surface forces. Both cohesion and adhesion of solids are strongly 
related to the surface energies of interacting objects. The minimum work 
required for the separation of two surfaces and therefore, the energy bonding 
them together is equal to the difference in free energy before and after
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separation. Such difference or change in free energy is defined as the work 
of adhesion Wa. The work of adhesion, Wa, between two materials C and D is 
given by:
Equation 1.9
Wa = A ( f  + yD- f D)
where A is the area produced by separation, y° and y° are the free energies 
per unit surface area of solids C and D in air respectively, and y°d is the free 
energy of the C-D interface per unit area. Thus for the same material C, the 
work of cohesion, Wc is described by the following equation:
Equation 1.10
Wc = 2 A f
Surface energy appears to exert a critical influence on the cohesive/adhesive 
properties of drug-drug and drug-excipient systems, considerably affecting 
mixing homogeneity as well as dispersion, de-aggregation and aerosolisation 
behaviour (Ahfat etal., 1997; Cline and Dalby, 2002).
1.2.2.4 Relative humidity
As previously discussed, the tendency for moisture to adsorb onto the 
surface of pharmaceutical dry powder particulates is significantly dependent 
on the relative humidity (partial water vapour pressure) of the surrounding 
environment, and the hydrophilic/hydrophobic characteristics of the surface 
of the material. Recent studies have focused on the role of relative humidity 
on the adhesive properties of powders (Hindle and Makinen, 1996; Price et 
al, 2002a; Price etal., 2002b; Harjunen etal., 2003; lida etal., 2004a; Young 
and Price, 2004). Relative humidity (RH) influences inter-particulate forces 
through two distinct mechanisms (Price etal., 2000). If a significant amount 
of water condenses between the surfaces of interacting particles, capillary
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forces may dominate particulate adhesion. However, the presence of a layer 
of water on the surface of interacting particles would increase the conduction 
of insulating materials and, thus, possibly dissipate the electrostatic charges 
which may be present upon contact. A relative humidity in the range of 40 to 
50% is considered to be the optimum environmental conditions for 
maintaining a lower degree of capillary and electrostatic influences. Above 
65% RH, capillary forces may significantly increase particle adhesion. At low 
humidities (< 30% RH) particle adhesion may be more susceptible to 
electrostatic forces due to triboelectriifcation upon powder handling 
(Podczeck etal., 1997a; Podczeck etal., 1997b). A more detailed review of 
the influence of relative humidity on inter-particulate forces therefore 
performance of dry powder formulations is presented in Chapter 5.
1.2.2.5 Surface texture and contact area
Since particulate interactions are effectively a surface phenomenon, the 
morphology of the surface will have a critical effect on the adhesive 
properties of interactive particles (Kawashima etal., 1998a; Zeng etal., 
2000a; Price etal., 2002b; lida etal., 2003b; Larhrib etal., 2003a; lida etal., 
2004b). Theoretical predictions of particulate interactions are usually based 
on the assumption that particles exhibit an ideal spherical shape with a 
smooth surface, or that a spherical particle adheres to a perfectly flat smooth 
surface (Wen and Kasper, 1989; Wang, 1989; Chew and Chan, 2001). 
However, in reality this is not the case, since pharmaceutical solids are 
known to exhibit a diverse variety of shapes and surface topographies. 
Particle-particle and particle-surface interactions can be classified into three 
main cases: (a). Spherical particles adhering to either a smooth surface or 
coarser spherical particles having a smooth surface, only in such a case it is 
possible to quantify adhesive forces acting between interacting surfaces, (b). 
Spherical or irregularly shaped particles adhering to a surface with relatively 
small scale asperities, which would dramatically decrease the contact area, 
thereby, increasing the separation distance and consequently decreasing
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adhesive forces, (c). Spherical or irregularly shaped particles adhering to a 
surface with relatively large scale asperities. In this case, adherent particles 
may mechanically interlock, leading to an increase in contact area and a 
decrease in separation distance between the two interacting bodies, resulting 
in higher adhesive forces (Otsuka etal., 1988; Wen etal., 1989; Taheri and 
Bragg, 1992; Mizez, 1994).
In view of the above, if we examine a carrier-based dry powder inhaler 
system for example, some of the fine drug particulates may adhere to smooth 
regions of the carrier surface whilst others may adhere to rougher sites 
displaying relatively small scale asperities, or even fall therefore become 
entrapped into bigger scale crevices that can accommodate them 
(Figurel .4). When exposed to external forces such as turbulent air 
fluidisation, particles adhering to smaller scale asperities may be easier to 
dislodge disperse and de-aggregate from the surface of carrier particles 
compared to those attached to the smooth regions, again due to increased 
contact area in the later situation thus significant increase in particle-particle 
adhesion. In contrast however, particles entrapped in the bigger scale 
crevices are the most difficult to remove, therefore requiring the highest 
energy to dislodge them from the surface of the carrier particle. In light of the 
above, it was found that it is rather imperative to obtain an optimised degree 
of surface rugosity in order to attain a desirable balance between adherence 
and detachment of drug particulates from the surface of carrier particles 
(Kassem and Ganderton, 1990; Byron etal., 1996; Staniforth, 1996; Heng et 
at., 2000; Zeng etal., 2001c; Clarke etal., 2002).
A more comprehensive understanding of the role of surface morphology is 
necessary to controllably modify the efficiency of drug delivery from carrier 
based dry powder inhalation formulations.
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(A ) (B ) (C )
Figure 1.4. Diagrammatic representation of different particle-surface 
interactions. Spherical particle adhered to a flat smooth surface (A), spherical 
particles adhered to a surface with relatively small scale asperities (B) and 
finally entrapment of a particle within a large scale crevice (C).
1.3 DPI formulation development
The basic concept of applying local medical treatment to the respiratory tract 
via the inhalation of ‘dusts’ evolved as a consequence of the therapeutic use 
of penicillin in the late 1940s (Bell, 1992). Despite numerous attempts to 
develop devices that would effectively deliver such therapeutic clouds, it 
wasn’t until the 1960s, that the first successful dry powder inhaler, the 
Spinhaler® was introduced for the delivery of high dose disodium 
cromoglycate (Bell etal., 1971).
Over recent years, dry powder inhalers (DPIs) have successfully undergone 
further advances, since they were genuinely considered as favourable 
systems for pulmonary delivery over existing conventional pMDIs and 
nebulisers. For example, dry powder inhaler systems overcome the use of 
environmentally harmful volatile propellants, such as CFCs or HFAs. 
Furthermore, DPIs are considered to be more patient friendly, since 
dispersion and entrainment of drug particles entirely depends on the 
inhalation efforts of the patient, therefore alleviating problematic issues of 
actuation and inhalation synchronisation. Moreover, DPIs are relatively 
inexpensive and not cumbersome as nebulisers, thus highly portable. In
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addition the engineering design of DPI devices allows the possible delivery of 
high drug doses (Timsina etal., 1994; Ashurst etal., 2000).
As previously discussed, and given the specific particle size of drug 
particulates (< 5 pm) that is vital for the deep delivery to the conducting 
airways, respirable-sized particles are intrinsically cohesive due to their large 
surface area and the dominance of the physical forces acting. Such 
pronounced cohesiveness renders the powder poorly flowable and hinders 
the ease of handling during manufacturing processes such as mixing and 
capsule filling (Ganderton and Kassem, 1992). The most common and 
reasonable solution that would address this shortcoming, is to co-process the 
fine drug particulates with larger carrier particles of an inert excipient. The 
carrier particles are usually designed to be of such a size that they deposit in 
the oropharynx after inhalation (Hinds, 1999).
In order for the drug particulates in a carrier-based DPI system to reach the 
desired regions of the respiratory tract, they must detach from the surface of 
the carrier particle during inhalation, otherwise they are most likely to face the 
same fate as the carrier particles, that is impaction in the upper airways. This 
key process is critically dependent upon the adhesive bonding that is created 
between the drug and carrier particulates. This emphasises the importance of 
attaining some sort of balance between the inter-particulate forces 
encountered in an interactive binary mixture (Staniforth etal., 1982; Begat et . 
a/., 2004; Dickhoff etal., 2005). The drug particulates need to be sufficiently 
adhered to carrier particles during mixing, in order to aid in blend 
homogeneity, accurate dose metering, device filling, also preventing 
segregation and formulation instability upon handling and storage. Yet, at the 
same time, drug particulates need to be able to be detached from the carrier 
particles upon actuation to form a fine particle cloud. It is this balance of 
particulate interaction that is required for efficient and successful 
development of DPI systems (Ganderton and Kassem, 1992; Prime etal., 
1997; Clarke etal., 2002).
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1.3.1 Carrier particles
Carrier particles are mainly utilised as a bulking agent (a ‘diluent’) to improve 
the flowability of the active ingredient, aid in accurate dose metering and 
enhance efficient device clearance. Although a number of excipient materials 
have been used as carriers (diluents), the traditionally used lactose remains 
the most commonly and frequently used carrier in pharmaceutical 
preparations of dry powder inhaler formulaitons. This is mainly because of its 
history as an inexpensive, inert, stable and safe excipient (Timsina etal., 
1994; Karhu etal., 2000).
For currently marketed dry powder formulations, the only approved excipients 
are lactose and glucose (British Pharmacopoeia, 1993). However more 
recently, several studies have been conducted as to the evaluation of other 
types of sugars in DPI systems such as mannitol, sorbitol and trehalose 
(Naini etal., 1998; Chew and Chan, 1999; Tee etal., 2000; Bosquillon etal., 
2001; Steckel and Bolzen, 2004).
The materials used as carriers for DPI formulations should exhibit a high 
degree of chemical and physical stability, be readily available in an 
acceptable pharmaceutical grade and with low hygroscopic characteristics. In 
addition, the excipient materials should easily metabolised and cleared from 
the airways upon inhalation delivery. In most cases, lactose particles are 
prepared by crystallisation, and can therefore be obtained in a variety of 
shapes and sizes (Jelen and Coulter, 1973a; Jelen and Coulter, 1973b; 
Raghavan etal., 2000; Raghavan etal., 2001). Lactose is known to have two 
anomeric forms, namely a and |3, both are present in aqueous solution with 
a/|3 ratio close to 40/60, but only the a-lactose crystallises spontaneously 
below 93.5°C. a-Lactose monohydrate is considered to be a preferential 
carrier in DPI formulations due to its particular “tomahawk” shape of its 
crystals which allows significant area for drug-excipient interaction. Typical 




Figure 1.5. Representative scanning electron photomicrograph of commercial 
crystalline grade a-lactose monohydrate (Lactochem®) particles.
1.3.2 Carrier particle size
On account of the fact that particle size is one the most crucial elements 
affecting inter-particulate interactions, the size of lactose carrier particles has 
been found to affect the delivery of drug particulates within a DPI system. 
Lactose can be readily produced in a wide range of particle size distributions. 
However, inhalation grade lactose is most commonly produced in the particle 
size range between 63 and 90 pm (Bell etal., 1971). Several studies have 
focussed on the influence of the size of carrier particles on the delivery 
performance of DPI formulations (Kulvanich and Stewart, 1987; Zeng etal., 
2000b; Clarke etal., 2001; Dickhoff etal., 2003; Islam etal., 2004b; Louey et 
ai, 2004a; Louey etal., 2004b).
Kassem et at. for example, investigated the effect of different size fractions of 
lactose on the respirable fraction of salbutamol sulphate from 1:67.5 ordered 
mixtures tested at various flow rates. The investigation indicated that the 
smaller sized carrier particles showed a higher respirable fraction of
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salbutamol sulphate regardless of the variation in flow rate (Kassem etal.,
1989). Such results were in accordance with those obtained by Steckel and 
Muller. Their study also indicated that reduction in carrier size was reported 
to improve budesonide aerosolisation (Steckel and Muller, 1997b). In a 
similar manner, increased deposition profile of disodium cromogiycate was 
observed following the use of smaller size ranges of lactose and glucose 
carriers (Braun etal., 1996). In addition, higher fine particle fraction of 
salbutamol sulphate was obtained from carrier particles exhibiting a size of 
less than 63 pm, compared to those in the size range of 63-90 pm (Zeng et 
a!., 2000b).
Although not well understood, a plausible explanation why drug particulates 
are easily detached from finer carrier particles may possibly be that adhesive 
inter-particulate forces are directly influenced by the decrease in particle size. 
Another possible suggestion is that drug particulates adhering to larger 
carrier particles are more liable to loss due to impaction of the later onto 
inhaler walls and upper conducting airways. Furthermore, it is thought that 
fine carrier particles can more easily disrupt the agglomerates of drugs 
exhibiting high cohesive nature (Begat etal., 2004).
The influence of carrier particle size is rather controversial, since findings of 
some other studies were contradictory to the aforementioned literature. For 
example, a study conducted by Byron etal. indicated that coarser lactose 
particles (53-105 pm) were shown to yield a higher deposition profile of 
terbutaline sulphate compared to finer lactose particles (< 53 pm) (Byron et 
at., 1990). It is significantly important to note however, that the concentration 
of fine lactose particulates should be controlled, since an increase in the 
deposition profile of the drug upon increasing the carrier particle size may be 
in part due to the presence of considerable amounts of fine carrier 
particulates. It is extremely crucial, therefore, that such studies are conducted 
on the effect of particle size of inherent carriers under equivalent conditions, 
that is to say similar concentrations of fine carrier particulates.
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1.3.3 Addition of fine excipient particles
Over recent years, extensive and meticulous investigations have been 
conducted as to the exploration of the influence of fine carrier particulates on 
the performance efficiency of DPI formulations. In fact, the inclusion of 
controlled and specified amounts of fine particulates is considered as one of 
the most significant and well recognised advances in the optimisation of 
pulmonary drug delivery. Scientific literature is enriched with various studies 
aimed at the methodical scrutiny of its critical influence in DPI systems 
(Clarke etal., 1998; Lucas etal., 1998b; Zeng etal., 1998; Zeng etal., 1999; 
Tee etal., 2000; Zeng etal., 2000c; Louey and Stewart, 2002; Islam etal., 
2004a).
In order to obtain a more fundamental insight into the effect of added fine 
carrier particulates, some studies have involved a pre-treatment step to 
remove intrinsic fines from carrier particles. Such pre-treatment procedures 
have involved either air jet sieving, direct blowing of compressed air through 
coarse carrier particles. Certain doubts however have been raised as to the 
efficiency of such procedures in removing the presence of intrinsic fine 
particulate material.
A study carried out by Larhrib and co-workers investigated the aerosolisation 
efficiency of salbutamol sulphate from formulations exhibiting different grades 
of coarse lactose. The formulation displaying the highest proportion of fine 
particulates (< 5 pm) was found to yield the greatest respirable fraction of 
salbutamol sulphate upon inhalation (Larhrib etal., 1999). Similar findings 
were also observed in a study by Tee and co-workers which investigated the 
influence of fines not only in lactose based formulations, but also with 
mannitol and sorbitol coarse carriers. Again formulations containing coarse 
carriers with the highest proportion of fine particulates resulted in improved 
drug aerosolisation efficiency (Tee etal., 2000).
Another critical issue that has been taken into consideration is the 
concentration (percent w/w) by which fines are included to powder
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formulations. The inclusion of 1.5 to 9% w/w of fine particulates generally 
resulted in a significant increase in fine particle dose of the drug (Zeng etal., 
1998). Similarly, the observation of a study carried out by Islam etal. 
suggested that the highest fine particle fraction of salmeterol xinafoate was 
achieved upon the inclusion of 15% w/w fine lactose particles. Coarse 
lactose particles in this study were processed by a wet decantation with 
alcohol procedure to remove intrinsic fine particulates (Islam etal., 2004a; 
Islam etal., 2004b).
Such findings clearly highlight the significance of optimising the amount of 
fines incorporated in a DPI formulation. There are, however, several related 
issues to the addition of fines. Studies have indicated that their addition may 
affect the flow properties of the formulation (Lucas etal., 1998a; Tee et ah, 
2000). Furthermore, increasing concentration of fines was found to increase 
the fraction of drug retained in the inhaler device. Such observations have 
been attributed to the increased adhesive inter-particulate interactions 
between fine carrier and drug particulates (Podczeck, 1999).
A number of theories have been employed in order to try to gain a better 
understanding of the ambiguous mechanisms by which fine carrier 
particulates tend to enhance the aerosolisation efficiency of carrier based 
systems. One of the proposed theories relies on the concept of the ‘active 
sites’ phenomena (Srichana etal., 1998b; Zeng etal., 1998; Bennett etal., 
1999; Larhrib etal., 1999; Tee etal., 2000; Zeng etal., 2001c). This theory 
suggests that fine carrier particulates preferentially adhere to high surface 
energy strong adhesion ‘active sites’, thus forcing drug particulates to bind to 
the low energy weak adhesion sites. The ‘active sites’ theory is presented 
and discussed in more detail in Chapter 4. Upon patient inspiration, the 
weakly bound drug particles are more easily liberated from the surface of the 
carrier particle, thereby facilitating more efficient aerosolisation.
Zeng etal. highlighted that formulations produced by first blending the coarse 
and fine carrier particles resulted in higher fine particle fractions than those 
produced by first blending the coarse carrier and drug particles (Zeng etal.,
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1999; Zeng etal., 2000c). Meanwhile, Lucas etal. revealed that for certain 
active ingredients, the order of blending is of no true significance and had no 
apparent effect on the performance of ternary DPI formulations. In fact, it was 
suggested that fine carrier particles and drug particles tend to redistribute 
themselves over the coarse carrier surface to form aggregated colonies or 
what is called ‘fine particle multiplets’ (Lucas etal., 1998a). The premise of 
‘fine particle multiplets’ was also supported by Soebagyo and Stewart and 
further advocated by of the studies of Louey and Stewart. Such ‘multiplets’ 
are considered to exhibit the desired effect of being more easily detached 
from coarse carrier particles since they exhibit a greater detachment mass, 
thus higher drag forces and kinetic energies, therefore tend to overcome 
adhesion with the coarse carrier and de-agglomerate more easily (Soebagyo 
and Stewart, 1985; Louey and Stewart, 2002).
1.3.4 Effect of surface roughness on drug delivery
The surface roughness of carrier particles is undoubtedly one of the most 
crucial determinants governing particulate interactions via either cohesion or 
adhesion. The bulk manufacturing of most commercially available excipients 
involve the subjection of excipient materials to a number of unavoidable 
rather vigorous industrial procedures Such as mechanical milling. As a result, 
physical instability is commonly introduced. Such physical instability could 
manifest itself in various aspects. One is that particles tend to exhibit evident 
changes in the topographical features such as apparent surface irregularities 
due to the presence of crevices (fissures, peaks and troughs). Another 
aspect of physical instability lies in the introduction of crystalline disorder, 
thus occurrence of variations in surface free energy (Begat etal., 2003). 
Such thermodynamically unstable regions on the surface are the likely to 
engage drug particulates during mixing via the influence of their high surface 
free energy. As previously introduced, if carrier particles tend to display a 
rough surface structure on a micrometer scale, then the fraction of drug 
particulates entrapped into the carrier surface crevices is almost unlikely to
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become dislodged under the application of turbulent airflow due to strong 
adherence via mechanical interlocking. Furthermore, it is thought that such 
crevices also act as a shelter for any entrapped drug particulates rendering 
them unavailable to the drag forces generated by inhalation air stream. In 
view of the above and given the unpredictable effect of physical instability 
due to variations in surface rugosity, it may be beneficial to carry out some 
sort of pre-treatment of carrier materials, prior to their use in DPI 
formulations. Such treatments are thought to possibly limit inter and intra 
batch variations of carrier materials, thereby, enhancing uniformity and 
reproducibility of in vitro and in vivo performance of DPI formulations.
Kassem and Ganderton studied the aerosolisation performance of 
salbutamol sulphate from formulations exhibiting three kinds of lactose 
carriers having different surface smoothness. The highest level of surface 
smoothness was demonstrated by lactose particles that were recrystallised 
from solution. It was further reported that the highest respirable fraction of 
drug particulates (< 5 pm) was obtained from formulations employing lactose 
carriers with a lower degree of surface rugosity (Kassem and Ganderton,
1990).
Indeed, physical characterisation of a-lactose monohydrate carrier particles, 
in terms of their surface roughness, has been shown to be of significant 
importance with regards to manipulating the adhesive properties governing 
particulate interactions in a powder formulation (Kawashima etal., 1998a; 
Podczeck, 1998c; Zeng etal., 2000a; Ferrari etal., 2004; Flament etal., 
2004). However, the degree of surface roughness of the carrier particles 
should ideally be optimized to manipulate the inter-particulate surface 
adhesion to allow high therapeutic delivery of the active ingredient, while 
exhibiting sufficient adhesion in preventing segregation of the powder upon 
handling (Ganderton and Kassem, 1992).
Over recent years, various attempts have been carried out in order to modify 
the surface characteristics of lactose carrier particles. Previous attempts 
include increasing surface smoothness via complete recrystallisation of
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carrier particles (Kassem and Ganderton 1990), high speed wet granulation 
(Colombo etal., 2000; Ferrari etal., 2004), crystal engineering involving 
modifying both the shape and surface rugosity of lactose particles through 
crystallization (Larhrib etal., 2003a) and surface treatment achieved by 
wetting with an aqueous-alcohol solution (lida etal., 2003; Islam etal., 
2004a). Furthermore, surface treatment via the use of ternary components 
such as magnesium stearate and leucine was also investigated (Staniforth, 
1996; Lucas etal., 1999; Young etal., 2002). One problem with the resulting 
particles, however, is that they may possibly exhibit relatively unpredictable 
alterations of surface morphologies due to relative difficulties in controlling 
the processing and treatment conditions. Chapter 3 focuses on the various 
methodologies utilised in modifying carrier surface morphological features 
and its implications and their influence on carrier-drug inter-particulate 
interactions and, thus, formulation performance.
1.4 Aim of the study
In spite of the successful advances in the area of inhalation technology over 
many years, one of the primary goals remains. That is the development of an 
expedient, efficient dry powder inhaler system with a reproducible 
performance, independent of the active ingredient. Formulations aspects 
such as optimising physicochemical characteristics of drug and carrier 
particles and achieving inter and intra batch equivalence were found to 
substantially minimise undesirable repercussions on drug delivery 
performance.
The surface rugosity of an excipient particle, in a carrier based inhalation 
formulation, has been shown to play a critical role in the behaviour of 
respirable drug particles. The surface texture of a commercial grade carrier 
particle is usually rough on a micrometer scale, with an array of asperities 
and clefts on its surface. These sites are thought to be related to areas of 
high surface free energy, providing a desirable and preferential area to which
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active drug particles are readily attracted and strongly adhered. It would, 
therefore, be highly advantageous to dramatically decrease the degree of 
high surface free energy sites by producing a surface with a well-defined 
surface roughness on a nanometre scale.
The primary aim of the study is to investigate the influence of nanometre 
scale roughness on drug-excipient adhesion properties and consequently the 
aerosolisation properties of respirable particles. A novel temperature 
controlled surface etching process has been developed to controllably modify 
the surface smoothness of commercial grade excipient particles. Qualitative 
characterisation of the surface morphology of the modified excipient particles 
was determined through a number of methodologies. Quantitative analysis of 
the deposition profile of model drug particles from different surface-smoothed 
excipient particles was also performed.
Moreover, the potential use of surface etched lactose carriers for low dose 
drug delivery was further studied. Additional investigative work was also 
dedicated to achieve a more comprehensive understanding of the 
prospective influence of environmental conditions on the stability and 
reproducibility of DPI formulations, and the manner in which the 
physicochemical properties of the excipient materials play in the overall 
stability of a DPI formulation.
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Chapter 2
General materials and methods
2.1 Materials
2.1.1 Pharmaceutical excipients
a-Lactose monohydrate (Lactochem®) was supplied by Borculo Whey 
(Chester, UK). The lactose was vibrated through a nest of sieves to obtain 
63-90 pm sieve fraction, which was used throughout the study. Fine particle 
a-lactose monohydrate (Sorbolac 400) was supplied by Meggle 
(Wasserburg, Germany). a-Lactose monohydrate is a disaccharide and its 







Figure 2.1. Chemical structure of a-lactose monohydrate.
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2.1.2 Active pharmaceutical ingredient
Salbutamol sulphate was the therapeutic active ingredient that was employed 
as a model drug for aerosolisation performance investigations. Micronised 
salbutamol sulphate was supplied by Aventis Pharma (Cheshire, UK). 
Salbutamol sulphate is a (32-adrenergic agonist which acts as a 
bronchodilator, its chemical structure is shown in Figure 2.2.
Figure 2.2. Chemical structure of salbutamol.
2.1.3 Solvents
Methanol (HPLC grade) was supplied by Fisher Chemicals (Loughborough, 
UK). Glacial acetic acid was supplied by BDH (Poole, UK). Ultra pure water 
was produced by reverse osmosis (MilliQ, Millipore, Molsheim, France). All 
solvents used throughout the study were at least of analytical grade.
2.2 Methods
2.2.1 Particle size analysis
A number of methods could be applied for the measurement of the particle 
size distribution of pharmaceutical excipients and active drug materials. Such 
methods include sieve analysis, time of flight determination, sedimentation,
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mercury porosimetry, low angle laser light scattering (LALLS) and impaction 
based techniques. The methods of choice that were found purposeful for the 
particle size distribution measurements throughout the study were low angle 
laser light scattering (LALLS) and impaction based techniques, utilising two 
standard method; the twin stage impinger (TSI) and the multi stage liquid 
impinger (MSLI). It is important to note however, that LALLS determines the 
actual geometrical particle size, whereas impaction based techniques 
describe the aerodynamic diameter of particles (Hinds, 1999). The 
aerodynamic diameter for a particular particle is defined as the diameter of a 
spherical particle with a density of 1 g/cm3 that has basically the same 
settling velocity as the particle in question. It is clear from the definition that 
the aerodynamic diameter is a standardised description for the shape 
(sphere) and the density (1 g/cm3) due to the diverse irregularities of shape 
which most pharmaceutical ingredients exhibit. Impaction based techniques 
are routinely used for the in vitro efficiency testing of inhaler formulations 
performance due to the correlation between aerodynamic diameter properties 
and sedimentation behaviour of the aerosol particles in the lung and 
aerodynamic diameter (de Boer etal., 2002; de Boer etal., 2004; Weda et 
al., 2004). The impinger methods are described in more detail in section 
2.2.7.3.
The LALLS technique is considered as a preferable technique for the 
characterisation of particle size distributions in pharmaceutical research and 
industry (Clark, 1995b; de Boer etal., 2002). In simple terms, particle size 
distribution analysis by LALLS involves measuring the intensity and pattern of 
the diffraction of a monochromatic, collimated light which is scattered 
following the passage of a laser beam through a particulate sample. The 
intensity and pattern of diffraction of the scattered light are a specific 
representation of an individual particle size. However, for micron-sized 
particles, the optical properties of the material are to be considered and light 
scattering in this case is described by the Mie theory (Allen, 1990). The Mie 
theory states that the induction of light scattering is triggered by the 
difference between the refractive indices of the particle and the surrounding 
medium.
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On the whole, when a sample with a range of particle sizes is presented for 
analysis, the scattering pattern is obtained by integration over the whole 
range of single scatters caused by each particle present in the sample. 
Particle size distributions are then calculated by matching the experimental 
and theoretical diffractograms (British Standard, 1999).
All particle size analyses were determined using a Malvern Mastersizer X 
(Malvern Instruments Ltd, Malvern, UK). The instrument is equipped with a 
magnetically stirred sample cell with a capacity of approximately 20ml. A 
0.1% w/w lecithin / cyclohexane solution was used as a sample dispersant.
To deagglomerate cohesive powders, some samples analysed were 
sonicated for 5 minutes prior to measurement. A 300 mm lens was used, as it 
allowed the detection of particle size in the range of 1.2 to 600 pm. 
Approximately 1 mg of the material was suspended in the dispersant and 
continuously stirred in order to obtain an obscuration level of 20-30%. The 
particle size distribution was calculated and represented as a volume 
distribution, and was also characterized by the 10th, 50th and 90th percentile 
of the cumulative particle undersize frequency distribution. All samples were 
prepared and analysed in triplicate.
2.2.2 Scanning electron microscopy
The overall morphology of a-lactose monohydrate carrier particles that were 
employed throughout the study was investigated using the scanning electron 
microscope. Scanning electron microscopy (SEM) was effectively utilised for 
the description of both particle shape and surface topography of the carrier 
particles. Scanning electron microscopy (SEM) involves the creation of a high 
resolution image by the use of a collimated beam of electrons instead of light 
waves. A beam of focussed electrons is emitted from an electron gun. Such 
electron beam is scanned back and forth over a conductive sample. As a 
result of the high speed continuous sweeping of the electrons across the 
specimen, secondary electrons (weakly bound conduction-band electrons)
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are emitted from the surface due to the local irradiation. The signal produced 
by the emitted secondary electrons from the specimen is collected on a 
detector and interpreted to form the final image.
Representative powder samples were sprinkled on adhesive black carbon 
tabs, which were pre-mounted on aluminium stubs. A thin film of gold was 
vaporised onto the sample surface using a sputter coater (Model S150B, 
Edwards High Vacuum, Sussex, UK). Samples were then examined using a 
JEOL 6310 SEM (Japanese Electron Optics Ltd, Tokyo, Japan) at 10 KeV.
2.2.3 Specific surface area
Gas adsorption is commonly used to measure the surface area of materials 
by condensing the gas onto the surface and determining the amount 
adsorbed in producing a monolayer. The specific surface area of a-lactose 
monohydrate carriers were determined by nitrogen gas adsorption. For a gas 
of known molecular cross section area, the quantity adsorbed can easily be 
converted into surface area. Measuring the amount of gas adsorbed over a 
range of relative pressures enables the monolayer coverage to be 
determined by applying the Brunauer, Emmett and Teller (BET) equation 
(Brunauer etal., 1938). The linear form of the BET equation is given by:
Equation 2.1
P  1 ( C - l )  P
Va(Po-P)~VmC VmC Po
where P  is the relative partial pressure of probe gas, Va is total mass of gas 
adsorbed at the specific pressure P, Vm is the mass of adsorbed gas forming 
a monolayer coverage, P0 is the saturation pressure and C  is the BET 
constant which represents the affinity of the gas to the surface of the 
material. Subsequently, by plotting the transform of the equation the 





Using the BET equation to measure the surface coverage allows the 
calculation of the specific surface area (sa) by the use of the following 
equation:
Equation 2.3
sa =  VmNA o
where NA is Avogadro’s constant and a is the cross sectional area of the 
adsorbing species, which is equivalent to 0.162 nm2 for N2 (Gemini 2360 
Surface Area Analyzer Operator’s Manual V5.0, Micromeritics). Cooling the 
sample to the temperature of boiling liquid nitrogen (77 K) reduces thermal 
effects, enables efficient condensation of nitrogen onto the surface and gives 
thermal stability; thereby limiting variations in the saturation vapour pressure. 
Prior to analysis, it is necessary to dry the sample in order to remove 
condensed water from all the pores. Remaining water would freeze during 
analysis at 77 K, blocking the access of probe gas to the pores leading to 
erroneous measurements.
Surface area was determined by 5-point BET N2 adsorption using the Gemini 
2360 nitrogen adsorption apparatus (Micromeritics, Norcross, USA). Samples 
were accurately weighed into standard glass bulbs and were then dried at 
40°C to constant mass (16-20 hours) under a continuous stream of dry 
nitrogen using the FlowPrep 060 (Micromeritics, Norcross, USA). The partial 
pressure of N2 was adjusted by mixing the analysis gas with helium, to a 
maximum partial pressure of 0.2.
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2.2.4 X-ray powder diffraction
X-ray powder diffraction (XRPD) is the most commonly used method in 
investigating the order of crystal structures of pharmaceutical powder 
samples (Nakai etal., 1977; Rowe etal., 1994). XRPD briefly involves the 
measurement of a diffracted monochromatic X-rays as they pass through the 
atomic spacing which exits between the atoms in a crystalline material. The 
wavelength of X-rays, from 0.1 to 100 A, covers the range of molecular and 
ionic bond length. The shorter wavelength of the X-ray spectrum (1 to 2 A) is 
of most significance in examining crystal structures. The initial parameter 
measured is the angle of diffraction, which relates to the dimension of the 
interatomic spacing responsible for the diffraction via the Bragg equation 
(equation 2.4):
Equation 2.4
A = 2d sin 0
where A is the wavelength of the incident radiation, of is the interatomic 
spacing and 9 is the diffraction angle. By determining the interatomic spacing 
for a known crystal structure, the three-dimensions of the unit cell can be 
determined (Guinier, 1994). Due to the fact that XRPD reflects the given 
crystal structure, it can be used to determine the presence of different crystal 
structures and/or crystalline disorder such as the presence of amorphous 
regions. However, the use of X-ray diffraction spectra in the direct 
quantification and detection of the amount of amorphous materials present 
has been proved to be relatively unsuccessful (Saleki-Gerhardt etal., 1994). 
Although the strength of the diffraction increases as the volume of crystalline 
regions increases, the signal strength is subjected to spherical aberration as 
a result of the geometry of the apparatus.
X-ray powder diffraction spectra of a-lactose monohydrate samples were 
collected using a Phillips X-ray powder diffraction system (D5000, Bruker 
AXS, Cheshire, UK). The system consisted of the following components; 4 
kW X-ray generator (PW 1730/00), long fine-focus Cu target (PW 2273/20,
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,4=1.504 A), computer-controlled vertical diffraction goniometer (PW 1820/00) 
and Xe proportional counter (PW 1711/10) with a graphite monochromator 
(PW 1752/00). Settings were as follows; 2° to 39.960° 20, step size 0.036° 
26, step time 0.5 seconds, temperature 25°C.
2.2.5 Powder bulk and tapped density and flow
The flowability of pharmaceutical powders is considered as one of the most 
crucial characteristics, which influences more or less all industrial handling 
procedures that are fundamentally encountered with formulation 
development. In dry powder inhaler formulations, flow properties of both drug 
and carrier particles play a critical role in attaining effective drug content 
uniformity, since powders that flow well tend to produce mixtures with a 
better degree of order. Furthermore, good flow properties ensure 
reproducible capsule filling and possibly improved aerosolisation efficiency. 
The flowability of a material is influenced by a number of factors. These 
include bulk density, particle size distribution, particle shape and aspect ratio, 
inter-particulate forces and surface texture (Neumann, 1967). Several 
methods have been acknowledged to measure the flowability of powders, 
most of which rely on a table by which the measured property is related to a 
descriptive term for the flowability. Properties such as angle of repose, mean 
avalanche time (Aeroflow®; Kaye, 1997), compressibility and minimum orifice 
diameter (Flodex®) are commonly used.
Throughout this study, the flow properties of a-lactose monohydrate carriers 
were qualitatively characterised by compressibility, as measured by their bulk 
and tapped densities (Carr, 1965). The bulk density was determined by 
pouring a sample of the powder into a suitable polypropylene measuring 
cylinder. The mass and volume of the powder were recorded and the bulk 
density calculated. The same sample was then placed on a jolting volumeter 
(J. Engelsmann, Ludwigshaven, Germany) and compressed by subjecting it 
to 100 standard taps..The tapped volume was recorded. The tapped volumes
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after subsequent 100 tap sets were recorded until <2% volume change was 
observed across three consecutive readings. The tapped density was 
calculated from the tapped volume measurement and Carr’s compressibility 
index (CCI) was calculated from:
Equation 2.5
c c i ( % )  =  \ 0 0 p ' ~ pb 
p<
where pb is the bulk density and pt is the tapped density.
2.2.6 Dynamic vapour sorption
To investigate the influence of storage at various environmental conditions on 
the aerosolisation performance of various lactose formulations, the 
susceptibility of different lactose samples for water vapour adsorption was 
challenged using the dynamic vapour sorption (DVS). The influence of 
humidity on water sorption and subsequent de-sorption of a-lactose 
monohydrate samples was determined gravimetrically over a range of 
controlled relative humidities. In simple terms, the DVS is based on an ultra­
sensitive Cahn microbalance. Thus, the microbalance can accurately 
determine changes in mass of the sample with varying partial water vapour 
pressures. A sample and reference pans are continually perfused with 
nitrogen gas with a pre-set partial pressure of the solvent vapour probe in 
question. The instrument is housed in a temperature controlled chamber (5- 
85°C) and required humidities are generated by mixing dry and saturated 
vapour gases using a mass flow controller before passing over the sample 
and reference holders (Buckton and Darcy, 1995).
Moisture sorption of a-lactose monohydrate samples was determined using a 
DVS (DVS-1-system, Surface measurement systems Ltd., London, UK). 
Approximately 50 mg of sample was weighed into the sample cell and
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subjected to a 0-90% RH cycle, over 10% RH increments. Equilibration 
moisture content at each humidity was determined when the change in mass 
in relation to the recording time (dm/df) was 0.0002% min'1.
2.2.7 Dry powder inhaler formulations
2.2.7.1 Preparation of powder formulations
Lactochem® a-lactose monohydrate was sieve fractioned for 20 minutes 
using a sieve shaker (Endecotts sieve and sieve shaker, London, UK). A test 
sieve with an aperture width of 90 pm was placed over a test sieve with an 
aperture width of 63 pm. The retrieved 63-90 pm sieve fractioned lactose 
was subsequently blended with micronised salbutamol sulphate (median 
diameter, d50 4.79 pm) in a ratio of 67.5:1 w/w. The micronised salbutamol 
sulphate was sieved through a test sieve with an aperture width of 500 pm to 
break up any agglomerates formed during storage. The blending procedure 
involved initially adding a mass of lactose, approximately double the amount 
of salbutamol sulphate to be incorporated in the powder blend into a 
stoppered sample glass tube. The total mass of salbutamol sulphate was 
then directly weighed on top of the layer of lactose. The glass tube was 
stoppered and placed on a Whirlymixer (Fisons Scientific Equipment, 
Loughborough, UK) in a slanting position at 45° and mixed at maximum 
speed for 50 seconds. The blend was further diluted by the addition of 
lactose. The amount of lactose was equivalent to the total amount of drug 
and lactose in the glass tube. The glass tube was stoppered and mixed via 
the Whirlymixer, using the settings described above. The geometric addition 
of the lactose and mixing were repeated until all the lactose had been 
incorporated into the blend. The stoppered glass tube was then placed in a 
Turbula mixer and mixed at 46 rev.min'1 for a further 30 minutes. Powder 
blends were stored in a controlled environment of 44% relative humidity until 
required. The controlled environment of the ambient 44% relative humidity
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was obtained via the use of a saturated solution of potassium carbonate 
which was placed in a tightly sealed container (O’Brien, 1948).
2.2.7.2 Drug content uniformity and capsuie filling
Ten samples of approximately 30.0 ± 2 mg of the powder blend (equivalent to 
the amount in the final dosage capsule), were randomly taken from various 
positions from the final blend which was evenly spread over a clean surface. 
The concentration of salbutamol sulphate was measured by either 
fluorescence spectrophotometry or high performance liquid chromatography. 
These are described in detail in section 2.2.7.4. The ratio of salbutamol 
sulphate to lactose of each sample was determined, and an acceptable dose 
uniformity of the mixture was when the relative standard deviation RSD% 
was less than 6.0.
Hard gelatine capsules (Size 3) were filled with 30.0 ± 2 mg of the powder 
mixture, such that each capsule contained a nominal dose of approximately 
400 ± 30 pg of salbutamol sulphate. The filling was performed manually and 
filled capsules were stored in a controlled environment of 44% relative 
humidity until further required.
2.2.7.3 Formulation performance analysis
One of the most significant issues related to formulation development of DPI 
formulations is obtaining adequate deep lung delivery of the active 
pharmaceutical ingredient. As previously discussed, one of the most critical 
physical property which governs the behaviour of aerosolised particles when 
exposed to an air flow is particle size. It is important to note, however, that in 
case of drug particles for inhalation, the aerodynamic diameter is usually 
employed to characterise particle size, rather than their physical dimensions.
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Since inertial impaction is the most commonly applied mechanism through 
which the aerodynamic particle size of aerosols is determined, inertial 
impactors were efficiently designed to represent the size fraction of airborne 
particles. Thus, enabling valuable in vitro examination of aerosolisation 
performance of tested formulations. In simple terms, a single stage impactor 
comprises a jet or nozzle plate containing an orifice of a defined diameter 
that is located at a fixed distance from a flat horizontal collection surface. 
Particle separation and sizing is achieved by the successive increase in the 
velocity of the air stream as it passes through the progressively reduced 
orifices of the nozzle plates. Whilst the incoming particles are travelling along 
the streamline, they are subjected to two forces. The first one is the 
momentum built up as they travel along the streamline, and the second one 
is the friction force with the surrounding air stream at the point of changing 
the direction of the laminar flow. The later force would drive the particles to 
accelerate in the new direction of air flow. That is to say, an airborne particle 
will continue to move in the original direction of flow until it loses inertia, it will 
then ‘relax’ into the new direction of flow. The deposition of particles onto the 
collection surface placed in the path of the original direction of air stream is 
dependent on particle diameter and density, velocity and viscosity of air 
stream, as well as the diameter of the jet orifice through which the air stream 
flows (Marple, 1970; Mitchell and Nagel, 2004).
Two different systems were employed throughout the study in analysing 
aerosolisation efficiency of the prepared DPI formulaitons. Both systems are 
based on impinger systems, that is, the deposition of drug particles within the 
in vitro apparatus is via impingement onto a liquid surface rather than 
impaction onto a solid surface. The desired particle cut-off size of each 
specific stage of an impinger/impactor is a complex relationship between the 
inertial and drag forces in an air flow, and is critically related to the airflow 
rate being drawn through the apparatus.
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Twin-stage impinger
The twin-stage liquid impinger (TSI) apparatus was the first device to assess 
pulmonary drug delivery through inertial impaction which was implemented 
by the British Pharmacopoeia (BP) (British Pharmacopoeia Commission, 
1993). The TSI is used for initial screening of inhalation devices and 
formulations, since it does not provide size distribution data but rather divides 
an aerosol into a coarse oropharyngeal fraction and a fine pulmonary fraction 
(Hallworth and Westmoreland, 1987). A representative TSI apparatus 
(Copley Scientific Ltd., Nottingham, UK) is shown in Figure 2.3.
The TSI apparatus contains two stages and a representative throat. The first 
stage contains 7 ml of solution, while the 2nd stage has 30 ml of solution. The 
TSI was operated at 60 L.min'1 (± 2 L.min'1) to produce a cut-off mass 
median aerodynamic diameter of 6.4 pm between the two stages. The cut-off 
diameter of 6.4 pm is defined by the jet diameter of stage 1, which was 
measured as 13.84 mm. Dry powder formulations were aerosolised from a 
Cyclohaler® device (Novartis, Surrey, UK). Each capsule was tested at 60 
L.min'1 for 5 seconds, given a total inhalation volume of 5L. Flow rate was 
calibrated using a flowmeter (SCR2, Glass Precision, Eng. Ltd., UK). A 
vacuum pump achieved the required flow rate through the TSI. The pressure 
drop across the apparatus was adjusted by a needle valve flow regulator 
(solenoid valve timer) (Copley Scientific Ltd., Nottingham, UK). The flow rate 
achieved through the device was adapted according to the inner resistance 
of the inhaler device. The pressure drop across the inhaler, established by a 
60 L.min'1 flow rate, was set to 4.0 kPa in accordance with the USP (US 
Pharmacopoeia, 1992).
The capsule to be tested was placed in the Cyclohaler®, which had been 
specifically fitted with a moulded rubber mouthpiece for attachment to the 
throat piece of the TSI. Upon achieving of an air tight seal, the vacuum pump 
was switched on. The pump was allowed to run for 4 seconds prior to and 
post solenoid-valve actuation, to allow the pump to equilibrate. The 
deposition test was repeated for each drug-lactose blend for a minimum of
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five capsules. The concentration of drug in the stages of the assembly was 
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Figure 2.3. Schematic representation of a twin-stage liquid impinger, adapted 
from the British Pharmacopoeia, 2001, Volume II.
Multi-stage liquid impinger
The multi-stage liquid impinger (MSLI) apparatus, unlike the TSI, was 
developed to enable the determination of an aerodynamic particle size 
distribution of an aerosol, which is considered critical in respect of the 
deposition of particles in vivo. It also offers another advantage which lies in 
the fact that it is calibrated to measure the particle size of an aerosol at flow 
rates ranging from 30 to 100 L.min'1. A representative MSLI apparatus 
(Copley Scientific Ltd., Nottingham, UK) is shown in Figure 2.4.
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The impaction surfaces of the MSLI consist of sintered-glass discs immersed 
in the liquid (dilution solution). The MSLI apparatus consists of a throat, four 
classifying stages into which 20 ml of the dilution solution are introduced 
such that the entire surfaces of all the glass plates are wetted through 
capillary action. And a fifth dismantled stage on top of which a fiber glass 
filter paper is placed. Upon achieving an air tight seal, single capsules 
containing the nominal dose of 400 ± 30 pg of salbutamol sulphate were 
actuated via a Cyclohaler® (Novartis, Surrey, UK) at 60 L.min'1 for 5 seconds. 
The device is specifically fitted with a moulded rubber mouthpiece for 
attachment to the throat piece of the liquid impinger. The flow rate was 
adjusted using a rotary vein pump and solenoid-valve (Copley Scientific Ltd., 
Nottingham, UK) and calibrated using a reference flowmeter (SCR2, Glass 
Precision, Eng. Ltd., UK). The pressure drop across the inhaler, established 
by a 60 L.min'1 flow rate, was set to 4.0 kPa in accordance with the USP (US 
Pharmacopoeia, 1992). The pump was allowed to run for 4 seconds prior to 
and post solenoid-valve actuation, to allow the pump time to settle.
The concentration of drug in each stage was determined by rinsing with the 
dilution solution both the inner wall and the collection disc of the 
corresponding stage, followed by tilting and rotating the apparatus. The 
device, metal throat and the filter were also washed for drug extraction. The 
cut-off mass median aerodynamic diameters were 13.0, 6.8, 3.1 and 1.7 pm 
for stages 1, 2, 3 and 4, respectively, at 60 L.min'1. Aerosol particles below
1.7 pm are collected on the filter stage. The respirable dose was calculated 
as the total mass of the drug found in the relevant impinger stages (stages 3, 
4 and 5) representing an effective cut-off diameter < 6.4 pm. The 
concentration of drug in the stages of the assembly was determined by either 







Figure 2.4. Schematic representation of a multi-stage liquid impinger, 
adapted from the British Pharmacopoeia, 2001, Volume II.
2.2.7A Drug analysis
The quantitative determination of drug concentrations in both blends content 
uniformity investigations and in vitro aerosolisation efficiency testing of 
formulations was carried by employing either fluorescence spectroscopy or 
high performance liquid chromatography (HPLC).
Fluorescence spectroscopy
Quantification of salbutamol sulphate content uniformity and in vitro 
deposition was determined by fluorescence spectroscopy (F-2000 Hitachi,
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Ltd. Tokyo, Japan) with the following settings: excitation wavelength, 279nm; 
emission wavelength, 305nm. The mobile phase and wash solution used 
throughout was water. Linearity was determined between 1 and 10 pg ml'1. 
Samples were diluted appropriately. a-Lactose monohydrate did not interfere 
with the salbutamol sulphate fluorescence response.
High performance liquid chromatography (HPLC)
Drug concentrations from both blend content uniformity testing and collected 
from various device components and TSI/MSLI sampling stages during in 
vitro studies were mainly analysed by high performance liquid 
chromatography (HPLC). Concisely, the HPLC operates by separating the 
organic compounds relative to their affinity for the solid phase in the HPLC 
column. The liquid chromatograph system was equipped with an autosampler 
(AS-950, Jasco, Tokyo, Japan), a pump (PU-980, Jasco, Tokyo, Japan), a 
column oven (CO-866, Jasco, Tokyo, Japan) and a UV/VIS-detector (UV- 
975, Jasco, Tokyo, Japan). Data were recorded and integrated using AZUR- 
OSIRIS Chromatography Software V 3.0. (Theix, France). Each value was 
determined by comparing the peak area of the sample to reference peaks of 
standard solutions of known concentrations. Each sample concentration was 
determined in duplicate.
A Sperisorb® 15 cm, 5 pm ODS1 column (Waters, Milford, MA, USA) was 
used for the analysis of salbutamol sulphate. Salbutamol sulphate was 
analysed using a mobile phase consisting of a 60:40 % v/v ratio of methanol 
to water mixture with 0.1% v/v of acetic acid. The HPLC pump was operated 
at a flow rate of 1.25 ml.min'1 and a pressure of approximately 400 kg.m2.
The injection volume was 100 pi. The employed wavelength of the detector 
was 276 nm. The analysis run time was 4 minutes and the retention time for 
salbutamol sulphate was approximately 2 minutes.
Standard solutions of salbutamol sulphate were prepared prior to HPLC 
analysis. Duplicate stock standard solutions were prepared by accurately
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weighing 10 mg aliquots of salbutamol sulphate into two 100 ml volumetric 
flasks and dissolving to volume with the mobile phase solution. Each stock 
solution was ultrasonicated for no more than 10 minutes to ensure 
dissolution, and then left to cool at room temperature and made up to the 
mark with the mobile phase solution. Working standard solutions were 
prepared by a carrying out a serial of dilutions of the stock standard solution 
using calibrated (class A) volumetric laboratory pipettes and the same mobile 
phase solution. A series of working standard solutions with concentrations 
comprised between 0.05 pg.ml'1 and 10 pg.ml'1 were subsequently prepared 
for salbutamol sulphate.
In order to correlate UV-absorbance response to drug concentration, the 
concentration-peak area response for salbutamol sulphate was investigated 
through linear regression analysis which is shown in Figure 2.5. A coefficient 
of determination (R2) of 1 for salbutamol sulphate inferred a direct response 
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The average and deviation of normal distribution populations were expressed 
as arithmetic mean (x ) and standard deviation (SD).
Arithmetic mean (x ) was calculated by:
Equation 2.6
The standard deviation (SD) of a pool of numbers was calculated using: 
Equation 2.7
The percent relative standard deviation RSD (%) also known as the 
coefficient of variation was calculated by:
Equation 2.8
Statistical analyses between different populations were carried out by one­
way ANOVA. A population was regarded as significantly different if the 
assumption of similarity was rejected with a probability greater than 95%. 






Novel temperature controlled surface etching of 
lactose particles for dry powder inhalation 
formulations
3.1 Introduction
The successful development of carrier based dry powder inhaler (DPI) 
formulations has been achieved through the design of ever increasingly 
elaborate devices and an improved understanding of the role of the 
interactions between the inhaler components, namely drug, carrier and 
device. Generally, a DPI is developed and optimised based on an iterative 
process of formulation preparation and testing. Excipient lactose particles, 
sourced from various suppliers, each exhibiting different physicochemical 
characteristics are invariably blended with micronised drugs, of various 
doses. The formulation is then studied using an in vitro aerodynamic particle 
size classifier, for example, a liquid impinger or a cascade impactor. The 
aerosolisation behaviour of the formulation is subsequently described in 
terms of the respirable fraction and emitted dose. The characteristic 
properties of the carrier, drug and processing conditions are then iterated to 
produce a formulation which exhibits a reproducible and acceptable dosage 
profile. This time consuming process has proved very successful by 
considering the plethora of products on the market which satisfy the stringent 
requirements of the relevant regulatory authorities (Smith and Parry-Billings,
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2003). However, there are many questions surrounding the nature and effect 
of particle interactions in a DPI formulation and it is clear that one lactose or 
drug type or batch or device will not provide universally optimal DPI 
performance. One of the key concerns within the industry is the inter and 
intra batch performance of lactose and the properties and characteristics of 
batches of the micronised drug (Byron etal., 1996). Indeed, it has been 
reported that inter-batch variations of lactose can influence formulation 
performance, especially for low dose drug formulations (Steckel etal., 2004). 
This can, in part, be explained in terms of particle size variations and surface 
roughness and, more importantly, how accurately the particle descriptors 
characterise both the lactose and drug.
The relationships between particle size and its distribution, shape and 
roughness, and aerosolisation behaviour have been investigated for carrier 
based DPI formulations. There have been reports of the effect of lactose 
source and particle characteristics on the efficiency of DPI formulations 
(Kawashima etal., 1998a; Larhrib etal., 1999; Louey etal., 2003). Recently, 
attention has focussed on the nature and role of the fine lactose particles on 
formulation performance and it has been suggested that the efficiency of a 
formulation can be optimised with a certain level of fines (Zeng etal., 1998; 
Islam etal., 2004a). However, the number of reports describing the 
relationship between the properties of the carrier and apparent formulation 
performance can be contradictory (Louey etal., 2003).
In view of the difficulties in understanding, predicting and comparing the 
relationships between carrier properties and drug particle interactions, both 
drug and excipient have been further processed to produce modified 
surfaces/particle size distributions which offer more reproducible and 
improved performance. Such approaches may ultimately allow the production 
of carriers which exhibit improved batch to batch consistency and stability. A 
similar approach has been used for drugs where drugs, such as salbutamol 
sulphate, have been engineered by crystallisation (Larhrib etal., 2003a) and 
by supercritical fluid technology (Shekunov etal., 2003; Rehman etal., 2004; 
Schiavone etal., 2004; Young and Price, 2004).
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The modification of lactose can be divided into three general areas; 
crystallisation, where lactose is crystallised from a lactose solution; solution 
phase processing, where lactose is exposed to a liquid media where partial 
dissolution/etching may occur; and dry processing, where lactose is ‘treated’ 
by, for example, co-processing in the absence of a liquid. These 
methodologies attempt to increase the aerosolisation of drug via geometric 
and morphological modifications. The relationships between lactose surface 
roughness, crystal aspect ratio and geometry and drug aerosolisation have 
been studied by crystallisation of lactose from water (Zeng etal., 2000a), 
water/acetone (Larhrib etal., 2003b) and carbopol/water/ethanol (Zeng etal., 
2001b; Larhrib etal., 2003a). These investigations reported an increase in 
aerosolisation of salbutamol sulphate and terbutaline sulphate with 
decreasing lactose roughness compared to ‘as supplied’ lactose. This is in 
agreement with a recent study of the relationship between the surface 
roughness of sieved lactose and aerosolisation of terbutaline sulphate 
(Flament etal., 2004). It has also been reported that increasing the surface 
roughness of lactose increases the emitted dose, but reduces the sub 6.4 pm 
respirable dose (Heng etal., 2000). Solution phase processing of lactose has 
been achieved by treating lactose with various liquids. Aqueous alcohol has 
been used to partially dissolve surface asperities resulting in an increase in 
the aerosolisation of salbutamol sulphate (lida etal., 2003a). Lactose has 
also been treated by decantation with alcohol to remove lactose fines which 
resulted in a decrease in the aerosolisation of salmeterol xinofoate which was 
restored after the re-addition of fines (Islam etal., 2004a). Additionally, 
lactose has been treated or ‘smoothed’ with a suspension of magnesium 
stearate in water/ethanol under high shear which resulted in an improvement 
in the performance and efficiency of a DPI formulation (Young et al, 2002). 
Such processes may result in some degree of dissolution or etching of 
lactose and the dissolution of fines from the crystal surfaces and it was not 
clear if part of any apparent improvement in the aerosolisation performance 
was due to modification of the particle size or the distribution of fines, since a 
reduction in carrier particle size has been reported to improve drug 
aerosolisation (Steckel and Muller, 1997b; Louey etal., 2003). Non liquid 
based treatment of lactose has been achieved by dry blending with leucine to
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improve functionality (Staniforth, 1996a; Lucas etal., 1999). It can be also 
argued that addition of lactose in the form of fine particulates to coarse 
lactose is another form of dry co-processing.
One problem with these types of investigations is that “modification” of a 
lactose sample invariably results in a change in the particle size and surface 
characteristics. It is practically impossible to absolutely classify particles in 
terms of their particle size distribution and surface roughness. This has 
obvious implications for both carrier and drug and explains the difficulties for 
quantitative comparisons of formulation performance. The relationship 
between modification and particle size distribution is further complicated by 
the possible methodology dependence of apparent particle size descriptors 
(Larhrib etal., 1999). The previously described reports suggest that for single 
dose devices, a decrease in lactose surface roughness together with an 
optimal level of fines should result in an improved lactose carrier 
performance, which again will be drug and device dependent. Obviously, the 
production of a lactose carrier which would facilitate classification would be 
attractive since it would reduce the effect of any possible batch to batch 
differences. As part of the efforts undertaken to develop multi-purpose DPI 
lactose carriers, this study describes an investigation into a novel particle 
surface etching process developed to evaluate the influence of carrier 
modification on the delivery of salbutamol sulphate from a model carrier 
based DPI formulation.
3.2 Materials
a-Lactose monohydrate (Lactochem® crystals) was supplied by Borculo 
Whey (Chester, UK). The lactose was vibrated through a nest of sieves to 
obtain a 63-90 pm sieve fraction, which was used throughout the study. 
Micronised salbutamol sulphate was supplied by Aventis Pharma (Holmes 
Chapel, UK). Water used was purified by reverse osmosis (MilliQ, Molsheim,
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France). All solvents used throughout the study were supplied by BDH 
(Poole, Dorset, UK) and were of at least of analytical grade.
3.3 Methods
3.3.1 Solubility profile of a-lactose monohydrate
An accurate temperature-water solubility profile for a-lactose monohydrate 
was determined. A supersaturated solution of lactose in water was prepared 
by continued addition of lactose to 20 ml of water. The solution was placed in 
a controlled temperature water bath at differing temperatures (Haake, DC5, 
Fisons Scientific Equipment, Loughborough, UK) and vigorously shaken for 
48 hours. Each equilibrated sample was rapidly filtered under vacuum 
through a 0.2 pm filter. The recovered solution was weighed and dried in an 
oven at 50°C. The resulting dry mass was re-weighed and solubility 
calculated. Solubility of a-lactose monohydrate was determined between 
20°C and 45°C at 5°C intervals.
3.3.2 Preparation of surface etched a-lactose monohydrate
The surface etching of lactose was achieved as follows. A saturated solution 
of a-lactose monohydrate, in water, was prepared and continually stirred at a 
constant temperature of 25°C. Temperature within the vessel was controlled 
to within 0.1 °C via a refrigerated controlled water bath (Haake, DC5, Fisons 
Scientific Equipment, Loughborough, UK). A known volume of the saturated 
solution (100 ml) was removed from the vessel, filtered and transferred to a 
dissolution cell, which was maintained at the saturation temperature. A pre­
determined amount of 63-90 pm sieved a-lactose monohydrate (Minjtiai), e-g- 
50 g, was added to the saturated solution in the dissolution cell. Surface 
controlled etching of the lactose particles surfaces was achieved by either
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ramping the temperature within the dissolution vessel at a controlled rate 
(0.1-0.5°C.min'1) or directly increasing to the etching temperature. The 
difference between the starting, 25°C, and the final temperature is referred to 
as the etching temperature, while the degree of etching can be directly 
quantified via utilising the following expression for undersaturation (a):
Equation 3.1
%ounder= - ^ V ^ x 1 0 0
'-'s
Where Ct is the solubility of lactose at the etching temperature and Cs is the 
solubility at the saturation temperature.
With prior knowledge of the temperature dependence of the solubility of a- 
lactose monohydrate, the undersaturation conditions and therefore the 
degree of or etching (%Metched), of the sieve fractioned crystals could be 
directly quantified. If the mass of added sieved lactose is greater than the 
‘dissolution capacity’ of the liquid, the percentage dissolved lactose, in terms 
of mass of the sieved lactose added, can be accordingly quantified via the 
following expression:
Equation 3.2
%Metched = ACT(%)V|_(ml)/Mjnjtial(9) 
for Minitial(9) ^ ACT(%)VL(ml)/100
Where ACj is the difference in the solubility of lactose in the solution at the 
saturation temperature and at the etching temperature. Minitiai is the original 
mass of 63-90 pm sieve fractioned lactose added to a known volume of the 
saturated lactose solution (V|_). ACt(%)Vi_/100 is the ‘dissolution capacity’.
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3.3.3 Particle size analysis
The particle size distributions of the untreated and surface etched lactose 
samples were determined by laser light scattering using a Malvern 
Mastersizer X (Malvern Instruments Ltd, Malvern, Worcs, UK). The 
instrument is equipped with a magnetically stirred sample cell with a capacity 
of approximately 20 ml. A 0.1% w/w lecithin/cyclohexane solution was used 
as a sample dispersant. To deagglomerate cohesive powders, each sample 
was analysed prior and post 5 minutes ultrasonication, hence, ensuring a 
more accurate assessment of the fine particulate content. A 300 mm lens 
was used, as it allows the detection of particle size in the range of 1.2 to 600 
pm. Approximately 1 mg of the material was suspended in the dispersant and 
continuously stirred in order to obtain an obscuration level of 20-30%. The 
particle size distribution was calculated and represented as a volume 
distribution. All samples were prepared and analysed in triplicate.
3.3.4 Scanning electron microscopy
Scanning electron microscopy (SEM) was used to characterise particle 
shape and surface morphology of powder samples. Representative powder 
samples were sprinkled on adhesive black carbon tabs, which were pre­
mounted on aluminium stubs. A thin film of gold was vaporised onto the 
sample surface using a sputter coater (Model S150B, Edwards High 
Vacuum, Sussex, UK). Samples were then examined using a JEOL 6310 
SEM (Japanese Electron Optics Ltd, Tokyo, Japan) at 10 KeV.
3.3.5 Specific surface area
The surface area of the untreated and surface etched lactose was 
determined by a BET adsorption method (Gemini, Micromeritics Ltd, USA)
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using nitrogen and helium gas. Samples were dried under a stream of dry 
nitrogen at 40°C for 16-20 hours prior to analysis.
3.3.6 Powder bulk and tapped density and flow
Powder flowability was represented by bulk and tap density measurements. 
The bulk and tap density of each lactose sample was obtained by adding 50- 
100 ml of powder sample into a 100 ml measuring cylinder. The initial volume 
and mass was recorded and then sample was subjected to 100 standard 
taps using a jolting volumeter (J. Engelsmann, Ludwigshaven, Germany), 
and the tapped volume recorded. The volume after subsequent 100 tap sets 
were recorded until <2% volume change was observed across three 
consecutive readings. Bulk, tap densities and Carr’s compressibility index 
were calculated.
3.3.7 X-ray diffraction
X-ray diffraction of untreated and surface etched lactose samples was 
obtained using an X-ray powder diffraction system (D5000, Bruker AXS, 
Cheshire, UK). Settings were as follows; 2° to 39.960° 20, step size 0.036° 
26, step time 0.5 seconds, temperature 25°C.
3.3.8 In vitro aerosolisation studies
The relationship between carrier surface etching and the in vitro performance 
of drug-carrier blends was investigated using a twin stage impinger (TSI). 
Micronised salbutamol sulphate, the most commonly used short acting (32- 
antagonist used in asthma therapy, was used as a model drug. The 
micronised salbutamol sulphate (median diameter, dso 4.79 pm) was
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geometrically blended with the untreated and surface etched lactose samples 
at a ratio of 67.5:1 w/w using a Whirlymixer (Fisons Scientific Equipment, 
Loughborough, UK) in 50 second pulses.
Upon completion of the geometric mixing, the blend was placed in a Turbula 
(Bachofen, Basel, Switzerland) and blended at 46 rev.min'1 for 30 minutes. 
The final blend was stored in a tightly sealed container with a saturated salt 
solution of potassium carbonate, which produced a relative humidity of 44% 
RH at 25°C (O’Brien, 1948). Prior to in vitro studies, content uniformity were 
investigated by analysing the drug content in 30.0 ± 2 mg samples (n=10) for 
each blend.
Quantification of salbutamol sulphate content uniformity and in vitro 
deposition was determined by fluorescence spectroscopy (F-2000 Hitachi, 
Ltd. Tokyo, Japan) with the following settings: excitation wavelength, 279nm; 
emission wavelength, 305nm. The mobile phase and wash solution used 
throughout was water; Linearity was determined between 1 and 10 pg.ml'1. 
Samples were diluted appropriately. a-Lactose monohydrate was shown not 
to not interfere with the salbutamol sulphate fluorescence response (Young 
and Price, 2004), when using water as a dilution solvent.
Hard gelatine capsules (Size 3) were filled with 33 ± 4 mg of powder blend, 
such that each capsule contained a nominal dose of 482 ± 58 pg of 
salbutamol sulphate. The aerosolisation properties of the salbutamol 
sulphate-lactose formulations were investigated using an apparatus A (British 
Pharmacopoeia), the twin stage impinger (TSI) (Copley Instruments Ltd, 
Nottingham, UK). The first stage contained 7 ml of water and the second 
stage contained 30 ml of water. At 60 L.min'1, the cut-off mass median 
aerodynamic diameter was 6.4 pm between the two stages (Hallworth and 
Westmoreland, 1987). Each capsule was tested via actuation for 5 seconds 
using the Cyclohaler® (Novartis, Surrey, UK) single shot dry powder inhaler 
device. The pressure drop across the apparatus was calibrated using a 
micromanometer (model FC012, Furness controls, Bexhill, UK). The flow rate 
was achieved using a rotary vein pump and solenoid-valve (Copley Scientific,
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Nottingham, UK), and adjusted using a calibrated flow meter. The pump was 
allowed to run for 4 seconds prior to and post solenoid-valve actuation, to 
allow the pump time to settle. The volume of air drawn through the in vitro 
apparatus was set at 5L. The concentration of drug in each stage/device was 
determined by washing the content of each stage into a volumetric flask with 
water before chemical analysis with the pre-calibrated fluorescence 
spectrophotometer (F-2000 Hitachi, Ltd. Tokyo, Japan). Each in vitro test 
was repeated for each drug-lactose blend for a minimum of five capsules.
The aerosolisation characteristics were described as: loaded dose (LD), drug 
recovered from the capsule, mouthpiece, throat and stages 1 and 2; emitted 
dose (ED), drug emitted from the device into mouthpiece adapter, throat and 
stages 1 and 2; fine particle dose (FPD), drug in stage 2 of the TSI; fine 
particle fraction (FPF), percentage of FPD to LD; delivered dose, percentage 
ED to LD.
3.4 Results and discussion
3.4.1 Solubility profile of a-lactose monohydrate
a-Lactose monohydrate is considered to be freely soluble in water (British 
Pharmacopoeia), exhibiting a solubility of 1 g in 4.63 ml water at 25°C 
(Handbook of Pharmaceutical Excipients). Accurate values were determined 
and were found to be fitting those obtained from literature (Jelen and Coulter, 
1973a; Thurlby and Sitnai, 1976). The experimentally determined water 
solubility values of lactose at varying temperatures are presented in Table 
3.1.
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Table 3.1. Aqueous solubility values of a-lactose monohydrate with varying 
temperatures.
The solubility versus temperature profile was fitted with a 3rd order polynomial 
equation. The relationship exhibited a correlation coefficient, R2, of 0.999.
The influence of temperature on the solubility profile of a-lactose 
monohydrate is shown in Figure 3.1. The solubility dependency can be 
modelled by the following expression:
S(T) = 19.892 -  0.2937T + 0.0138T2 + 0.00003T3
Where S(T) is the solubility of lactose in water (g/100ml) at a specific 
temperature and T is the temperature of the solution in °C.
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y = 19.892 - 0.2937X + 0.0138x2 + 0.00003x
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Figure 3.1. Aqueous solubility profile of a-lactose monohydrate.
3.4.2 Surface etched  a-lactose  m onohydrate
The variable etching conditions for surface modification of the lactose 
excipient particles were determined through knowledge of the solubility 
versus temperature profile. Once the saturation temperature, volume of the 
saturated solution and the mass of 63-90 pm sieve fractioned a-lactose 
monohydrate added to be etched are known, the temperature conditions for 
the etching process can be accurately determined and controlled. Table 3.2 
shows the percent undersaturation (%a) and accordingly the percent mass 
etched ( % M e tc h e d ) of 50 grams of sieve fractioned a-lactose monohydrate as 
a function of temperature difference (AT). The lactose particles to be etched 
were added to 100ml of solution that was saturated at 25°C.
63
Temperature difference
AT = T«tCh -  T„t (°C)
% Undersaturation
%o = -({Ct -C .} /C ,)x 100
% Of initial mass etched 






Table 3.2. Percent undersaturation and percent mass etched of a-lactose 
monohydrate at varying temperature differences.
This relationship is industrially scalable and requires only a limited number of 
additional steps to current industrial production and processing. It should be 
noted that unlike crystal growth at conditions of low supersaturation, the 
kinetics of dissolution are rapid. Furthermore, once saturation conditions 
have been achieved at the etching temperature, further dissolution and 
crystal growth are inhibited.
3.4.3 Physical characterisation
The effect of surface etching of a-lactose monohydrate on the aerosolisation 
of salbutamol sulphate was investigated. Prior to the aerosolisation studies, 
the untreated and surface etched lactose were initially characterised in terms 
of particles size, morphology, surface area, flowability and crystallinity.
3.4.3.1 Particle size analysis
A graphical representation of the particle size and cumulative undersize 
distributions of untreated and various % mass etched a-lactose monohydrate 
are shown in Figures 3.2, 3.3, 3.4 and 3.5. Each powder sample was 
analysed both with and without sonication. Untreated commercial a-lactose
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monohydrate was found to have a considerable level of fine particles, as 
observed upon sonication of the lactose sample Figure 3.2 B. Figures 3.3 
and 3.4 clearly indicate that no significant variation was observed between 
unsonicated and sonicated samples of 5% and 21% surface etched lactose, 
respectively. Comparison of the cumulative undersize data between 
untreated and all surface etched lactose samples is shown in Figure 3.5. The 
data highlights the removal of fines from the commercial lactose sample. No 
marked differences were observed between the different % mass etched 
lactose samples. The data suggested that the surface etching process 
modified the particle size distribution to a larger d50 and a reduction in the 
number of fines. These results also suggest that the temperature controlled 
surface etching process did not alter the overall particle size distribution of 
lactose excipient. The surface area of the surface etched lactoses, shown in 
Table 3.3, remained unchanged.
As previously stated, any apparent change in functionality may, in part, be a 
consequence of this removal of fines. The presence and level of fines in 
lactose carriers is widely reported as a crucial factor in DPI performance 
(Zeng etal., 1998; Zeng etal., 1999; Louey etal., 2003; Islam etal., 2004a).
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Figure 3.2. Cumulative particle size distribution of untreated a-lactose 
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Figure 3.3. Cumulative particle size distribution of 5% etched a-lactose 
monohydrate before (A) and following 5 minutes sonication (B).
67
1
2 0  - I r 100
C 18 O
16 - 
~  1 4 -
- 80 A






0.1 10 100 10001





















Figure 3.4. Cumulative particle size distribution of 21% etched a-lactose 
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Figure 3.5. Cumulative undersize distribution of untreated and various 
degrees of % mass etched a-lactose monohydrate.
3A.3.2 Scanning electron microscopy
Figure 3.6 shows SEM photomicrographs of the surface topography of as 
supplied commercial grade a-lactose monohydrate. Untreated lactose 
micrographs indicated a considerable degree of surface roughness with 
significant variations in surface properties of the lactose particles. In addition, 
there was a significant level of fine particulates of lactose present on the 
surfaces of the untreated sample, in strong agreement with particle size 
analysis data.
The specific influence of etching conditions on the surface texture of lactose 
was also examined by scanning electron microscopy. Representative 
scanning electron micrographs of controllably surface etched crystals of a- 
lactose monohydrate with increasing the degree of etching are shown in 
Figures 3.7, 3.8, 3.9, 3.10 and 3.11. Distinct differences are exhibited for 
each particular surface treatment.
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Figure 3.6. Representative scanning electron photomicrographs of untreated 
a-lactose monohydrate crystals at X500 (A) and X2000 (B) magnifications.
SEM photomicrographs of 5% surface etched a-lactose monohydrate 
particles, shown in Figure 3.7, clearly demonstrate an observable change in 
surface topography. Most noticeably, there is a visual decrease in the level of 
fines, accompanied by a dramatic decrease in the apparent surface 
roughness of lactose particles upon processing when compared to untreated 
lactose particles.
Figure 3.7. Representative scanning electron photomicrographs of 5% 
surface etched a-lactose monohydrate crystals at X500 (A) and X2000 (B) 
magnifications.
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Increasing the undersaturation conditions of the lactose solution to 12% 
indicated complete dissolution of the intrinsic lactose fines, as shown in 
Figure 3.8. This increasing in etching conditions further increased the degree 
of surface smoothness, without modifying the macroscopic morphology (i.e. 
particle size and shape) of the lactose crystal.
Figure 3.8. Representative scanning electron photomicrographs of 12% 
surface etched a-lactose monohydrate crystals at X500 (A) and X2000 (B) 
magnifications.
Further increasing the degree of undersaturation to 21% indicated complete 
elimination of irregularities, yet maintaining good binding sites for drug 
particles Figure 3.9.
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Figure 3.9. Representative scanning electron photomicrographs of 21% 
surface etched a-lactose monohydrate crystals at X500 (A) and X2000 (B) 
magnifications.
Since the apparent degree of surface dissolution increased with increasing 
the dissolution temperature, etching of a-lactose monohydrate particles 
surfaces at a degree of undersaturation exceeding 21% exhibited extremely 
smooth surface topography. However, noticeable alterations of crystal shape 
and morphology were observed in the representative SEM micrographs at 
32% and 44% mass etched lactose particles Figures 3.10 and 3.11.
Figure 3.10. Representative scanning electron photomicrographs of 32% 
surface etched a-lactose monohydrate crystals at X500 (A) and X2000 (B) 
magnifications.
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Figure 3.11. Representative scanning electron photomicrographs of 44% 
surface etched a-lactose monohydrate crystals at X500 (A) and X2000 (B) 
magnifications.
3.4.3.3 Specific surface area
Surface area measurements of unmodified and surface etched a-lactose 
monohydrate samples are shown in Table 3.3. It can be seen from Table 3.3 
that all the samples exhibited similar (ANOVA p<0.05) (n=3) surfaces areas 
of approximately 0.11 m2g'1 suggesting that etching does not have a 
dramatic effect on the bulk surface area of the processed lactose.
3.4.3.4 Powder bulk and tapped density and flow
The powder flow of untreated commercial grade and surface etched lactose, 
as represented by Carr’s compressibility index, is shown in Table 3.3. In 
general, the blends exhibited similar (ANOVA p<0.05) Carr’s compressibility 
indices of 21% ± 2 suggesting that the surface etching process did not 
dramatically change the flow properties of the powders. There were no 
significant differences between the bulk and tapped densities of the samples. 
Commercially available sieved lactoses of different mesh sizes (d50 135 to 55 
pm) also exhibit similar Carr’s compressibility indices and powder densities 
(Handbook of Pharmaceutical Excipients).
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Etching temperature (°C)
Untreated 5 10 15 25
Mass of lactose dissolved (%) - 5 12 21 44
Lactose surface area (m2g~1) 0.13 ±0.01 0.10 ±0.01 0.10 ±0.01 0.11 ±0.01 0.11 ±0.01
Carr's compressibility index (%) 19 ± 1 19 ± 1 24 ±1 18 ±1 24 ±1
Table 3.3. Specific surface area and Carr’s compressibility index values for 
untreated and various % mass etched a-lactose monohydrate samples.
3.4.3.5 X-ray diffraction
X-ray diffraction patterns for both untreated and 44% surface etched lactose 
are shown in Figure 3.12. No modification of the crystal structure upon 
surface etching was observed. Such observations are to be expected since 
the processing method does not induce crystal growth and a-lactose 
monohydrate is the most stable lactose form under such experimental 
conditions. The changes in the relative intensity of the diffraction lines are 
most likely due to the geometry of the crystals in the equipment and possibly 
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Figure 3.12. X-ray powder diffractogram for untreated and 44% surface 
etched a-lactose monohydrate samples.
3.4.4 In vitro ae ro so lisa tio n  s tu d ie s
The relative standard deviation in the content uniformity of the salbutamol 
sulphate-lactose blends was less than 3%. The TSI aerosolisation efficiency 
of salbutamol sulphate, as represented by FPD and FPF, is summarised in 
Table 3.4 and shown graphically in Figures 3.13 and 3.14.
Untreated 5
Etching temperature (SC) 
10 15 20 25
Emitted dose (pg) 350.8 ± 25.6 288.1 ±45.4 359.9 ±147.9 389.0 ± 55.2 371.0 ±16.6 435.3 ±18.2
Delivered dose (%) 82.2 ± 4.2 82.7 ± 1.8 71.5 ±21.7 82.2 ± 4.8 81.8 ±1.6 84.6 ± 2.2
Fine particle dose (FPD) (pg) 56.1 ±15.1 62.2 ±31.6 83.5 ± 9.4 108.3 ±47.2 88.4 ±11.1 102.7 ±9.5
Fine particle fraction (FPF) (%) 13.1 ±3.3 17.2 ±6.8 17.3 ±3.1 22.6 ±8.1 19.5 ±2.0 20.0 ± 2.0
Table 3.4. Deposition profile of salbutamol sulphate (mean ± standard 
deviation) in a TSI after aerosolisation of untreated and % mass dissolved 




No significant differences (ANOVA p<0.05) in either ED (451.8 ± 58.9 pg) 
and % delivered dose (-81%) were observed for all blends. The results, 
however, clearly indicated an increase in the deposition of the active 
salbutamol sulphate particles in the second stage of the TSI, upon modifying 
the surface texture of lactose particles. Particles deposited in stage 2, which 
has an effective cut off diameter of less than 6.4 pm, represent the fine 
particle dose (FPD). In comparison, analysis of the FPD and FPF suggested 
that surface etching at 35°C had a significant effect (>12%) on drug liberation 
(Fisher’s pairwise analysis, p<0.05). However, a decrease in fine particle 
fraction with further increasing the etching conditions was also observed.
This may be as a result of obtaining an extremely smooth surface at high 
etching temperatures exhibiting marked decrease in nanometer scale surface 
roughness, which may lead to an increase in the contact area between 
micron sized drug particles and the carrier surface. In such circumstances, 
the increase in contact area between drug and excipient may directly 
increase the force of adhesion and concomitantly the energy required to 
aerosolise the active particles upon inspiration. Given this effect, maintaining 
an optimum degree of carrier surface roughness is of great significance as 
schematically illustrated in Figure 3.15.
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Figure 3.13. Effect of surface etching temperature on the deposition profile of 
salbutamol sulphate in terms of % fine particle fraction.
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Figure 3.14. Effect of surface etching temperature on the deposition profile of 
salbutamol sulphate in terms of fine particle dose.
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Figure 3.15. Schematic diagram of proposed drug-carrier particles 
interactions as a function of increased degree of surface etching.
As previously stated, there are conflicting reports about the inter-relationships 
between lactose based carriers, micronised drugs and apparent formulation 
efficiency. It was reported that increasing the surface ‘smoothness’ of lactose 
improved the performance of inhalation formulations (Ganderton and 
Kassem, 1992). Presently, it is generally accepted that particle size, surface 
roughness and the level of fines are of significant importance. Lactose 
carriers have been modified using a variety of processes to produce excipient 
particles which exhibit improved aerosolisation properties. Such processes 
include the use of crystallisation techniques to produce ‘smooth’ crystals with 
well defined size descriptors (Zeng etal., 2000a; Larhrib etat., 2003b), 
complete recrystallisation of carrier particles to increase surface smoothness 
has also been investigated (Ganderton and Kassem, 1990). Importantly, 
however, the changes in smoothness of the lactose crystals did not improve 
the performance compared to the untreated lactose, which was explained in 
terms of the effect of presence of fines. The same workers reported that 
increasing the elongation ratio and smoothness results in an increase in 
aerosolisation of salbutamol sulphate (Zeng etal., 2000a). Additionally it has 
been reported that the ED, FPD and FPF of terbutaline sulphate increases
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with decreasing lactose roughness (Flament etal., 2004). The lactose used 
in this later study was air-jet sieved to lower the level of fines, reducing the 
effect of this variable. Lactose has also been ‘smoothed’ by solution phase 
treatment of lactose with ternary agents such as magnesium stearate and 
leucine (Staniforth, 1996a; Young etal., 2002), and dry co-processing with 
leucine (Lucas etal., 1999). All these methods were reported to result in an 
improvement in drug aerosolisation. Recently, lactose has been subjected to 
a wet granulation process using a high shear mixer to reduce surface 
roughness (Colombo etal., 2000). Another attempt of surface treatment 
included the wetting of lactose particles with an aqueous-alcohol solution 
(lida etal., 2002). This research study also suggests that decreasing the 
surface roughness of the lactose carrier results in an increase in FPD and 
FPF without affecting the ED. However, this is not a simple relationship since 
the etching process also resulted in an increase in the 50th percentile of 
particle diameter (d50) and a decrease in the level of fines.
However, in this present work, it is interesting to note that the 5% mass 
etched lactose sample exhibited a dramatic increase in d50 and reduction in 
fines but no increase in the aerosolisation of salbutamol sulphate. This is in 
agreement with a ‘smoothing’ study which also included an aqueous method 
which as well as smoothing the lactose also reduced the level of fines (Young 
etal., 2002). However, as observed for the 5% mass etched lactose sample 
in this study, this did not result in any improvement in lactose functionality. 
This would, in part, agree with the proposal that the presence of a certain 
level of fines improves the functionality of lactose (Staniforth, 1996a; Lucas et 
al., 1998a; Zeng etal., 1998; Zeng etal., 1999; Louey etal., 2003; Islam et 
al, 2004a) and agrees with the suggestion that removing fines and reducing 
the surface roughness of sieved lactose increases the performance of a DPI 
formulation (Flament etal., 2004). There are limitations however, for 
example, even though crystallisation processes can produce lactose with 
improved aerosolisation, increases in the crystal aspect ratio can be 
detrimental to formulation characteristics such as content uniformity and flow 
properties (Larhrib etal., 2003a).
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Quantitative comparisons with the literature are difficult due to the variations 
in the processing and source of the lactose employed and the methodologies 
utilised in particle size analysis. For example, the classification of a lactose 
sample based on sieving can be misleading since adhesion of fines to larger 
particles will always occur due to simple physics. This also confirms that the 
apparent particle size distribution of lactose may differ depending on the 
method of determination (Larhrib etal., 1999). These have obvious 
formulation implications. This was exemplified in a study carried out to 
determine the relationship between sonication time and the apparent particle 
size of untreated sieved lactose. Clear differences between the particle size 
distributions of the untreated lactose were observed. In general, sonication 
resulted in an increase in smaller particle fractions, most likely due to the 
separation of fines from the larger particulates. As expected, this was not 
observed for the surface etched lactose samples, correlating with the 
previously described SEM images. Minor differences in the particle size 
distribution were observed with increased dissolution etching temperature but 
the distribution profiles were very similar.
These observations show that a sieved lactose sample should be considered 
as a pseudo-ordered or interactive mix rather than a material defined by 
some experimentally determined size descriptor and that the particle sizing 
method should be developed to maximise the information from any particle 
size descriptors obtained. Clearly, the production of a modified lactose 
carrier, such as the temperature controlled surface etched lactose developed 
in this research study, may indeed offer improved aerosolisation of drug and 
formulation characteristics. Furthermore, facilitating a better understanding of 
particle size and functionality relationships by reducing the effect of the 
methodology of particle size determination.
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3.5 Conclusions
Overall it appears that there is a relationship, albeit a complex one, between 
lactose nominal particle size, particle size distribution (including fines) and 
surface topography. This present study suggests that the surface treatment 
of lactose via the controlled etching process with can control the particle 
surface properties and the removal of fines to produce carriers which 
increase the aerosolisation of salbutamol sulphate from a single dose inhaler. 
Additionally, such carriers may exhibit particle size characteristics which are 
less dependent on sizing methodology.
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Chapter 4
The influence of drug to carrier ratio on the delivery 
performance of low dose inhalation formulations
4.1 Introduction
Over recent years, extensive research studies have been conducted in the 
exploration of the ‘ideal’ formulation strategy upon which a satisfactory dry 
powder inhalation system can be routinely formulated (Newman etal., 1991; 
Staniforth, 1995; Labiris and Dolovich, 2003). The perception of such a 
strategy involves improving the flow properties and the aerosolisation 
characteristics of the respirable-sized therapeutic ingredient. As previously 
discussed, the requirement of a specific aerodynamic particle diameter for 
respiratory delivery (0.5-8 pm) (Ganderton and Kassem, 1992), involves 
subjecting the therapeutic material to high shear secondary processing, such 
as micronisation and milling (Vidgren etal., 1987).
The processing of the particles gives rise to highly cohesive (towards like 
particles) and adhesive (towards unlike particles) interactions. In an attempt 
to alleviate the undesirable shortcomings of having pronounced 
cohesive/adhesive properties, the micron-sized drug particles are commonly 
blended with coarse inert carrier particles. The binary interactive system 
created is termed as an ‘ordered mixture’ (Hersey, 1975). An ordered 
mixture, as described by Hersey, involves an interaction between substance
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A and substance B that are most likely of unequal size, weight and ratio, yet 
still contemplating a significant and acceptable degree of powder mixture 
homogeneity. In fact they are considered to be more homogenous than 
random mixtures. Hersey also suggested that a definite number of fine 
particles of substance A may adhere to a single large particle of substance B 
for any given binary system (Hersey, 1975).
It is well understood that a number of factors influence the interparticulate 
forces which dominate the interaction between substance A and substance B 
(Hersey, 1975; Staniforth, 1987). This ultimately influences the detachment of 
the fine particles of substance A from the surfaces of substance B. These 
factors include the physicochemical properties of both interacting substances 
and the environmental conditions under which the final mix was prepared, 
stored and used (Staniforth etal., 1981; Staniforth etal., 1982; Byron etal., 
1996; French etal., 1996; Price etal., 2002; Voss and Finlay, 2002).
Of all the physicochemical parameters governing the delivery performance of 
a dry powder inhaler system, the surface rugosity of an excipient particle is 
undoubtedly one of the key determinants in achieving effective pulmonary 
delivery. The industrial manufacturing of pharmaceutical excipients, such as 
lactose, is usually carried out through implementing various procedures 
which have long been used for the relatively large scale extraction of such 
excipients from their natural resources. That being so, the physical properties 
and stability of excipient particles are being constantly jeopardised. Such 
instability resides in obtaining particles that show evidence of irregularities in 
surface roughness parameters (peaks and troughs). Furthermore, specific 
regions with interchangeable (both) crystalline and amorphous domains are 
most likely to be introduced during processing. This may lead to considerable 
variations in surface free energy and electrical charge among the 
thermodynamically unstable sites upon their formation (Muster and Prestige, 
2002; Begat etal., 2003).
A combination of the factors discussed above contributed to the postulation 
of the ‘active site’ theory (Hersey, 1975). The ‘active site’ theory proposed
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that the surface of a large carrier particle consisted of distinct regions so 
called ‘active’ high adhesion sites and ‘passive’ low adhesion sites. Further 
development described the presence of these sites through the prediction of 
a surface energy map (Staniforth, 1996b). The surface energy map ideally 
forecasted ‘active’ sites as the sites that possess high surface energy, and 
‘passive’ sites as the sites that possess low surface energy. In a similar 
manner, sites that would yield equivalent adhesional forces between the drug 
and the carrier interacting surfaces were described as iso-energetic adhesion 
sites (Staniforth, 1996b).
Under these conditions, it is reasonable to assume that the active high 
energy sites existing on the surface of the carrier particle would be the ones 
preferentially filled with finer particles. The finer particles may either be drug 
particles, intrinsic/extrinsic fine carrier particles, and or fine particles of a 
ternary component.
The occupation, and thus the complete saturation of these active sites, would 
therefore be significantly dependant on the ratio of fine particulates which are 
incorporated into a binary system. The binary system will be one of two 
possible systems: (a). A system of a low ratio of fine particulates, where a 
considerable amount of fines are strongly adhered to the active sites, due to 
the sub-filling effect of such sites. (b). A system of a high ratio of fine 
particulates, leading to complete saturation of active sites due to the filling 
effect of these highly energetic sites. Thus, any remaining fines will be more 
weakly adhered to passive low energy sites of the excipient surface.
It is clearly evident that the presence of active sites would have significant 
implications to the drug delivery efficiency from a dry powder inhaler system. 
However, one can assume that the detrimental influence of active sites would 
be much more exacerbated if the DPI system was designed to deliver low 
doses of drugs having high therapeutic potency (e.g. formoterol fumarate 
which has a formulated dose of 6-12 pg). Since the amount of drug 
incorporated in such a system is expected to be way below the saturation 
limit of the active sites, this may result in strong drug-excipient adhesion
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behaviour, deviations from target doses and label claim may be a significant 
issue. On the other hand, the possible influence of active sites may not be of 
an issue for the majority of marketed DPI formulations which are aimed for 
the delivery of relatively high doses (e.g. Ventolin Accuhaler®, Ventodisks®, 
Pulvinal®, and Cyclohaler® >200 pg). This is due to the fact that a significant 
fraction of the nominal dose is actually utilised to fill the active sites, thus 
facilitating the detachment of the remaining part of the dose under any 
sufficiently given inspiratory effort.
Several approaches have been employed to overcome the unpredictable and 
disadvantageous effects of active sites. These approaches, for instance, 
include the use of increased fine particle content in order to enhance the 
filling of the potential active sites present on the surface (Lucas etal., 1998b; 
Zeng etal., 1998; Zeng etal., 1999; Louey and Stewart, 2002; Louey etal., 
2003). Another approach developed to tackle this issue involved modifying 
surface texture and rugosity (Colombo etal., 2000; lida etal., 2002; Islam et 
a!., 2004; Flament etal., 2004). In addition, previous studies have also 
investigated modifying the morphology through crystal engineering (Kassem 
and Ganderton, 1990; Kawashima etal., 1998a; Zeng etal., 2000a; Larhrib 
etal., 2003b). Moreover, another alternative mean which was also carried out 
was the use of a ternary force control agent (Staniforth et al., 1982; Lucas et 
al., 1998a; Lucas etal., 1999; Clarke etal., 2001; Young etal., 2002). In light 
of these findings there still remains a more comprehensive interpretation of 
the imperative role of active sites particularly for low dose drug delivery.
The primary aim of this part of the study is concerned with examining the 
influence of drug to carrier ratio on the aerosolisation performance of a model 
DPI system and the influence of the physical properties of lactose carrier. In 
order to achieve a more valuable insight into the rather ambiguous role of 
active sites, the drug to carrier ratio study was performed on dry powder 
formulations which exhibited different lactose carriers. The lactose carriers 
employed were untreated commercial grade a-lactose monohydrate, 
untreated air jet sieved lactose and surface etched lactose, which underwent
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treatment via the novel temperature controlled surface etching process, 
described in Chapter 3.
4.2 Materials
a-Lactose monohydrate (Lactochem® crystals) was supplied by Borculo 
Whey (Chester, UK). The bulk powder was vibrated through a nest of sieves 
to obtain a 63-90 pm sieve fraction, which was used throughout the study. 
Micronised salbutamol sulphate was supplied by Aventis Pharma (Cheshire, 
UK). Water used was purified by reverse osmosis (MilliQ, Molsheim, France). 
All solvents used throughout the study were supplied by BDH (Poole, Dorset, 
UK) and were of at least of analytical grade.
4.3 Methods
General methods of each technique or apparatus used in this study are 
described in detail in Chapter 2.
4.3.1 Preparation of powder blends
Powder formulations containing different dose levels of salbutamol sulphate 
were prepared by varying the ratio of salbutamol sulphate to lactose carrier. 
Eight blends with ratios ranging from approximately 1:100 to 1:5000 w/w 
were prepared with as received commercial grade a-lactose monohydrate. 
Seven blends with the same range of drug/lactose ratios were prepared 
incorporating the 5% surface etched a-lactose monohydrate. Finally, six 
blends again with the same range of drug/lactose ratios were also prepared 
with air jet sieved a-lactose monohydrate. The air jet sieved lactose was 
obtained via subjecting the commercial grade lactose to a further air jet 
sieving process, to remove intrinsic fines. Each formulation was designed
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such that each 50 mg of the powder blend contained the desired dose. The 
volume of the powder in the mixing cell was kept constant to reduce the 
effect of friction and to maintain reproducibility.
Salbutamol sulphate was blended with the lactose geometrically. Briefly, an 
amount of lactose, equivalent to about twice the total mass of salbutamol 
sulphate was used to ‘sandwich’ the drug between two layers of the lactose 
powder. This was mixed for one minute using a Whirlymixer (Fisons Scientific 
Equipment, Loughborough,UK). Lactose was then added in geometric 
quantities, mixing with a Whirlymixer for one minute upon each addition. The 
final blend was then placed in a Turbula (Bachofen, Basel, Switzerand) and 
blended at 46 rev.min'1 for a further 30 minutes.
The drug doses formulated with untreated commercial grade lactose were 
approximately 11 pg, 30 pg, 40 pg, 90 pg, 135 pg, 190 pg, 350 pg and 450 
pg. The drug doses formulated with surface etched lactose were 
approximately 32.5 pg, 43.5 pg, 63.5 pg, 117 pg, 180 pg, 345 pg and 437 pg. 
Finally, the dose levels formulated with untreated air jet sieved lactose were 
approximately 30 pg, 55 pg, 91 pg, 196 pg, 338 pg and 458 pg.
Each blend was stored in tightly sealed containers with a saturated solution 
of potassium carbonate (43% RH) for a minimum of 48 hours prior to 
analysis.
4.3.2 Drug content determination
Quantification of salbutamol sulphate content uniformity and in vitro 
deposition measurements were carried out by high performance liquid 
chromatography (HPLC). The HPLC system consisted of an AS950 
intelligent sampler, PU-980 intelligent HPLC pump, 975 UV/VIS detector (all 
Jasco, Japan) and Spherisorb 15 cm, 5 pm ODS1 column.
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The mobile phase used throughout the investigation was methanol/water 
(60:40) and acetic acid 0.1 % v/v. Settings were as follows; detection 
wavelength 276 nm; flow rate 1.25 ml.min'1; pressure approximately 400 
Kg.m2; injection volume 100 pi; analysis time 4 min; approximate retention 
time 2 min.
Linearity was confirmed between 0.1 and 10 pg.ml’1 (R2 = 0.999). Lactose 
was shown not to interfere with the salbutamol sulphate response. Sample 
injections were performed in duplicate using a bracket standard method 
containing standards prepared from separate stock solutions.
4.3.3 In vitro aerosolisation studies
The influence of drug-lactose ratio on the aerosolisation performance was 
investigated using the twin stage impinger (TSI) (Copley Scientific Ltd., 
Nottingham, UK). The methodology used followed that of the British 
Pharmacopoeia. Briefly the TSI contained 7ml of mobile phase in stage one 
and 30 ml mobile phase in stage two, which at 60 L.min'1 produced a cut off 
mass median aerodynamic diameter of 6.4 pm between the two stages. The 
flow through the TSI apparatus was controlled using a GAST rotary vein 
pump and solenoid valve timer (Copley Scientific Ltd., Nottingham, UK). Flow 
rate was tested prior to operation using a calibrated flow meter.
A filled (49.90 mg ± 0.20 mg) size 3 gelatine capsule was placed into the 
dosage chamber of the Cyclohaler®. The mouthpiece was attached to the TSI 
apparatus and the Cyclohaler® inserted until the end met the inner edge of 
the rubber mouthpiece. The pump was turned on and allowed to stabilise for 
4 seconds before starting the valve-timer for a 5 seconds period. The device 
was removed carefully; the empty capsule placed into a beaker, and the 
device was primed and tested with a second capsule. This procedure was 
repeated until 5 actuations had been conducted.
88
The TSI apparatus was then dismantled and each stage was washed with 
mobile phase into volumetric flasks. In addition, the device and capsules 
were washed into a separate volumetric flask. Appropriate sample dilutions 
were made prior to testing by HPLC. All values were divided by 5 to 
approximate a single dose.
The TSI aerosolisation studies were conducted in triplicate for each 
formulation and were randomised for dose.
4.4 Results and discussion
4.4.1 Particle size analysis
The particle size distributions for both lactose and salbutamol sulphate are 
shown in Figure 4.1 A and B, respectively. The size distribution for the 
commercial untreated a-lactose monohydrate lactose sample (volume 
median diameter) indicated that the majority of particles were between 60 pm 
and 200 pm in diameter. It is interesting to note, that the upper size was 
higher than the sieve fraction value (90 pm) and was most likely due to the 
“tomahawk” geometry of the lactose particles. Furthermore, approximately 
6% of the particles exhibited diameters of less than 20 pm, with 2% less than 
5 pm. These can be related to the presence of fine lactose particles attached 
to the large carrier particles which were visible using SEM (See section 
3.4.3.2). This demonstrated that simple sieving does not provide sufficient 
energy to remove adhered lactose fines from larger carrier particles and that 
lactose fractions produced by sieving consist of a pseudo-ordered mix which 
has obvious formulation implications. Analysis of the particle size distribution 
of micronised salbutamol sulphate suggested 90% of the particulates 
exhibited a diameter less than 9.4 pm and 50% less than 3.4 pm.
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The particle size distributions of both surface etched and untreated air jet 
sieved lactose samples are also presented in Figure 4.2 A and B. It was 
clearly evident from the particle size distributions, that untreated air jet sieved 
lactose exhibited a higher level of fine lactose particulates when compared to 
the surface etched lactose carrier. For surface etched lactose, approximately 
8% of particles exhibited diameters of less than 20 pm with around 4% less 
than 5 pm. Whereas for untreated air jet sieved lactose, approximately 25% 
of particles exhibited diameters less than 20 pm, with around 10% less than 
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Figure 4.1. Particle size distribution of 63-90 pm sieve fractioned commercial 
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Figure 4.2. Particle size distribution of 63-90 pm sieve fractioned surface 
etched lactose (A) and untreated air jet sieved lactose (B).
4.4.2 Scanning electron microscopy
Representative scanning electron microscopy (SEM) photomicrographs of 
unblended and blended surface etched lactose and untreated air jet sieved 
lactose particles are shown in Figures 4.3 and 4.4, respectively. The
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micrograph of the processed lactose particles suggest a distinct variation in 
the amount of intrinsic fines adhering to the surface of air jet sieved lactose 
with respect to surface etched lactose, which is clearly evident in Figure 4.3. 
The particle size analysis and SEM investigations indicate that the air jet 
sieving process does not adequately remove the desired degree of intrinsic 
fines. These data suggest that the temperature controlled surface etching 
process may offer a better processing technique for the accomplishment of a 
rather uniform particle size distribution with the removal of fine particulate 
material.
Representative SEM images of 12 pg, 135 pg and 450 pg dose blends of 
commercial grade a-lactose monohydrate are shown in Figure 4.5 A, B and 
C, respectively. Representative SEM images of 12.5 pg, 100 pg and 400 pg 
dose blends of surface etched a-lactose monohydrate are also shown in 
Figure 4.6 A, B and C, respectively. Clear variation in the degree of fine 
particulates (< 5 pm) were observed when comparing the blends from the 
lowest to the highest dose level. In general, a rank-order in fine particulate 
number matched that of the blend dose. Unformulated lactose SEM images 
of untreated commercial grade a-lactose monohydrate showed large carrier 
particles with some smaller adhering lactose particles which is in agreement 
with the previously described particle size data. A parallel argument can be 
made when examining the SEM images of both the untreated commercial 
grade and surface etched lactose blends as represented in Figures 4.5 and 
4.6. The three selected dose level blends of untreated commercial grade a- 
lactose monohydrate demonstrated a relatively higher presence of fine 
particulates on the larger lactose particles when compared to the almost 
equivalent dose level blends of the surface etched lactose. Such 
observations were further emphasised by the SEM photomicrographs of the 
same 400 pg dose level of surface etched and untreated air jet sieved 
lactose blends represented in Figure 4.4 A and B. The SEM photomicrograph 
of the 400 pg untreated air jet sieved lactose blend (Figure 4.4 B) not only 
displayed a higher level of fine particulates adhering on to the surface, but 
also, a rougher surface topology of the lactose particle was evident. One can 
therefore reason that the temperature controlled surface dissolution process
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had a significant effect on considerably minimising apparent particle surface 
irregularities.
Figure 4.3. Representative scanning electron photomicrographs of surface 
etched lactose (A) and untreated air jet sieved lactose (B).
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Figure 4.4. Representative scanning electron photomicrographs of 400 pg 
dose surface etched lactose (A) and untreated air jet sieved lactose (B) 
blends.
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Figure 4.5. Representative scanning electron photomicrographs of 12 pg (A), 
135 pg (B) and 450 pg (C) untreated commercial grade a-lactose 
monohydrate blends.
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Figure 4.6. Representative scanning electron photomicrographs of 12.5 pg 
(A), 100 pg (B) and 400 pg (C) surface etched lactose blends.
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4.4.3 In vitro aerosolisation studies
Content uniformity (50 mg samples) across each blend indicated a coefficient 
of variation less than 5% (n=10). The aerosolisation efficiency of salbutamol 
sulphate from the various lactose carriers was investigated using the twin 
stage impinger (TSI). Data was processed and represented as follows: 
loaded dose (LD), which was the drug recovered from the device/capsule, 
mouthpiece, throat and stages 1 and 2; the emitted dose (ED), was the drug 
recovered from the mouthpiece adapter, throat and stages 1 and 2; the fine 
particle dose (FPD), was the drug recovered from stage 2 of the TSI; and the 
fine particle fraction (FPF), which is the percentage of fine particle dose 
(FPD) to loaded dose (LD).
The relationship between emitted dose and loaded dose for the untreated 
commercial grade a-lactose monohydrate formulation is shown in Figure 4.7. 
The data suggested a linear response (R2 = 0.998) between loading and 
emission efficiency, with a nominal device removal efficiency of 89% ± 4% 
across all doses. A linear relationship was also obtained between the emitted 
dose and loaded dose for all three lactose carriers under investigation in this 
part of the study. Comparisons between untreated lactose and surface 
etched lactose and air jet sieved lactose are shown in Figures 4.8 and 4.9, 
respectively. This study suggested that the efficiency of the device at 
removing 50 mg bulk formulation was independent of lactose type or 
drug/lactose ratio. Moreover, since the percentage drug loss in the device 
was apparently independent of dose, it is therefore reasonable to assume 
that such losses are due to drug adhered to retained lactose, since the 
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Figure 4.9. Influence of loaded dose on the emitted dose. Comparison 
between untreated commercial grade, air jet sieved and surface etched 
lactose.
The relationship between fine particle fraction and loaded dose for the 
untreated commercial grade a-lactose monohydrate formulation is shown in 
Figure 4.10 and tabulated in Table 4.1. It can be seen from the graph that the 
loaded dose has a significant effect on the fine particle performance (ANOVA 
p<0.05). In general, a linear decrease (R2 = 0.977) in fine particle fraction 
was observed on increasing the dose from 11 pg to 135 pg followed by an 
increase when the dose was increased from 135 pg to 450 pg.
A rather similar trend was also obtained when examining the relationship 
between fine particle fraction FPF and loaded dose for the surface etched 
lactose formulation (Figure 4.11). It was noticeable, however, that the 
increase in FPF with increasing loading dose took place at a lower dose 
(Table 4.2). That is to say, a linear decrease (R2 = 0.958) in fine particle 
fraction was observed on increasing the dose from 32.5 pg to 63.5 pg 
followed by an increase when the dose was increased from 63.5 pg to 437 
pg which is significantly different than the increase that took place at the
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dose level of 135 |ig for the untreated commercial grade a-lactose 
monohydrate formulations. Furthermore, a significant difference in the 
aerosolisation efficiency (FPF) between untreated commercial grade and 
surface etched lactose was determined at the dose level of approximately 
100 pg and above (ANOVA p<0.05).
The logical conclusion from such observations would be related to the ‘active 
site’ theory. The surface smoothing of lactose particles resulted in a decrease 
in active sites, and if the quantity of these active sites are reduced, the point 
at which the linear decrease in FPF with loaded dose may decrease to a 
lower drug/lactose ratio. Conversely, an increase in the degree of ‘active 
sites’ may lead to the requirement for an initial higher loaded dose to achieve 
a linear relationship between fine particle delivery performance and loaded 
dose.
No considerable variation in the aerosolisation behaviour of untreated 
commercial grade and untreated air jet sieved lactose formulations at low 
and high drug/lactose ratios was determined, as indicated in Figure 4.12 and 
Table 4.3. Such an observation is expected since the surface of untreated air 
jet sieved lactose particles exhibited similar morphological properties to 
commercial grade lactose in terms of surface roughness as observed via the 
SEM photomicrographs. It is these variations in surface features that may be 
the source of the high energy active sites that are initially filled with strongly 
adhering drug particles at low doses. This would result in the need for a 
critical concentration of drug to saturate active sites. It is beyond this critical 
concentration that a further increase in the drug load (drug/lactose 
monohydrate ratio) may result in a linear increase in both FPF and FPD with 
loaded dose.
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Figure 4.12. Influence of loaded dose on the fine particle fraction. 
Comparison between untreated commercial grade and untreated air jet 
sieved lactose.
The relationship between fine particle dose and loaded dose of untreated 
commercial grade, surface etched and air jet sieved lactose formulations is 
shown in Figures 4.13 and 4.14. The data suggested that for the untreated 
commercial grade lactose formulations, the dose level only had a statistically 
significant effect on the FPD measurements once it was higher than 135 pg 
(ANOVA, Fishers’s pairwise p<0.05). Analysis of the FPD with loaded dose 
for the surface etched lactose formulations (Figure 4.14) indicated no 
significant differences in performance between loaded dose for 
concentrations up to 63.5 pg. Such observations suggest that since both 
samples were 63-90 pm sieve fractioned lactose that exhibited similar 
particle size distributions, and there was no evidence of drug agglomeration, 
the smoothing of lactose monohydrate resulted in a decrease in ‘active sites’. 
Thus, may provide the potential for improvement of drug aerosolisation at 
lower doses.
These observations above can be corroborated when investigating the
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FPF (Figure 4.11). As previously discussed, when studying untreated 
commercial grade formulations, a linear decrease in FPF was observed as 
the potential ‘active sites’ were filled resulting in no significant difference in 
FPD, prior to an increase. With the smoother surface dissolved lactose 
monohydrate (potentially containing less active sites), the slope and point of 
minimum linear decrease was reduced (minimum FPF at drug load = 63.5 pg 
R2 0.958 for the etched lactose, compared to a minimum of FPF at drug load 
= 135 pg R2 0.977 for the commercial grade lactose).
It is significant to note, however, that the relationship between the loaded 
dose and FPF across the dose range 63.5 -  437 pg for etched lactose and 
135 -  450 pg for commercial grade lactose was not perfectly linear (Figure 
4.11). This is to be expected however, since such a system would still 
contain a certain distribution of active sites below the critical adhesion limit 
and therefore potentially result in a non-uniform performance (i.e. the 
probability of drug-particle removal will be dependent on the filling of differing 
energy sites). Furthermore, the inherent particle size distribution of the 
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Figure 4.14. Influence of loaded dose on fine particle dose. Comparison




Commercial grade lactose 
ED (ug) FPD (pg) FPF (%)
12.1 ± 2.4 11.3 ± 2.3 1.2 ±0.1 10.5 ±1.8
29.7 ± 2.1 26.5 ± 2.3 2.8 ± 0.3 9.5 ±0.8
38.4 ± 0.8 35.2 ± 0.2 3.7 ± 0.3 9.6 ± 0.6
89.4 ±2.1 83.9 ± 2.5 5.8 ± 0.7 6.5 ±0.9
134.9 ±4.1 114.9 ±2.4 6.6 ±1.5 4.9 ±1.2
187.4 ±12.5 158.2 ± 18.4 14.2 ±7.7 7.4 ± 3.5
353.2 ±16.6 308.1 ± 17.8 47.8 ± 5.7 13.5 ±1.1
450.4 ±1.0 388.1 ± 10.9 66.4 ± 8.5 14.7 ±1.9
Table 4.1. Influence of loaded dose on the aerosolisation parameters of 
commercial grade a-lactose monohydrate formulations.
Loaded dose (pg) ED (pg)
Surface etched lactose 
FPD (pg) FPF (%)
32.5 ± 2.2 29.5 ± 2.4 4.2 ± 0.6 13.0 ±1.0
43.5 ± 1.3 39.3 ± 2.1 3.3 ±1.4 7.5 ±2.9
63.5 ± 0.8 52.1 ± 1.2 1.7 ±0.3 2.6 ±1.4
117.3 ± 1.1 100.9 ± 1.4 10.7 ±1.3 9.1 ±1.1
179.4 ± 10.3 150.7 ± 10.6 23.3 ± 2.2 13.0 ±1.6
345.3 ± 3.1 283.8 ± 4.6 65.4 ± 4.6 18.9 ±1.2
436.9 ± 7.2 363.0 ± 2.9 96.4 ±2.1 22.1 ±0.8
Table 4.2. Influence of loaded dose on the aerosolisation parameters of 
surface etched a-lactose monohydrate formulations.
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Loaded dose (pg) ED (pg)
Air jet sieved lactose 
FPD (pg) FPF (%)
29.4 ±1.4 26.7 ±1.4 4.1 ±0.9 13.9 ±3.0
54.7 ± 2.9 52.3 ± 2.5 3.3 ±1.6 6.0 ±2.5
90.8 ± 0.6 85.8 ±1.3 5.3 ± 0.6 5.8 ±0.7
196.2 ±8.5 178.1 ±9.0 19.7 ±3.6 10.0 ±1.5
338.1 ±4.1 297.4 ± 5.9 46.1 ±3.8 13.6 ±0.9
458.4 ± 4.2 407.3 ± 2.3 55.6 ± 4.9 12.1 ±1.1
Table 4.3. Influence of loaded dose on the aerosolisation parameters of air 
jet sieved a-lactose monohydrate formulations.
As previously discussed, there are many possible topographical features that 
a drug particle may encounter on a lactose surface, such features exhibit a 
considerable degree of variations in morphology and surface free energy as 
schematically represented in Figure 4.15 A. As a consequence of a 
combination of increased contact area, high surface free energy and simple 
geometric constraints, it is envisaged that sites with high energy (area 1 in 
Figure 4.15 A) on the carrier surface would be preferentially occupied 
compared to sites with low energy (area 2 in Figure 4.15 A).
A possible example of this is shown in Figure 4.15 B, where micron sized 
particulates have accumulated in a recess in the surface of a large lactose 
carrier particle.
Furthermore, it is suggested that the active sites present on the surface of 
the carrier will have a specific energy distribution (Figure 4.15 C) with a 
critical, average adhesion point below which particles, drug or lactose, could 
be removed. This concept correlates with previous studies, which have 
suggested that surface roughness and carrier material directly influence 





Figure 4.15. Schematic diagram of regions on a carrier surface (A) containing 
potential high energy (1) and low energy (2) ‘active’ sites. SEM of a crevice 
on a lactose carrier surface containing many micron sized particulates (B). 
Theoretical distribution and process of active site filling (C).
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Another point to consider is the potential for the formation of drug or drug- 
lactose fines agglomerates. Previous studies have reported that the presence 
of fines increase the fine particle fraction through the formation of 
agglomerates or multiplets (Lucas etal., 1998a). However, recent studies 
have suggested that the agglomeration or individual drug-carrier formation of 
a blend will be related to the balance of adhesion and cohesion in the system 
(Begat et al., 2004). It was suggested that for a salbutamol sulphate-lactose 
system, adhesion would dominate, thus reducing the potential for 
agglomeration (Begat etal., 2004). Such observations correlate well with the 
SEM images of the blends in this study, which suggested many of the 
micronised particulates in the salbutamol lactose system to be distributed as 
discrete entities. However, it is important to remember that the formulation 
mechanism will be dependent on the drug and carrier properties.
Recent studies by Louey etal. (2003) suggested that increasing the 
presence of lactose fines result in an agglomerate based system. This is 
likely, since the potential free carrier space would be reduced. Furthermore, it 
is envisaged that the fine particle fraction would eventually plateau and 
decrease due to multilayer or aggregate formation and formulation 
segregation.
Observations across the dose range 32.5 -  437 pg for surface etched lactose 
and 11 -  450 pg for commercial grade lactose suggested that the 
disadvantageous influence of so called ‘active sites’ on the aerosolisation 
performance has a more dominant effect on formulations aimed at low dose 
drug delivery and that such influence becomes less disadvantageous upon 
increasing dose concentration above a critical value. Clearly many variables 
would influence this relationship and are worth considering for future 
investigation. These include quantifying the influence of inherent fines and 




Clear variations in the fine particle dose and fine particle fraction were 
observed as a function of drug load or drug/lactose ratio. The relationship 
between drug/lactose ratio and aerosolisation performance was related to the 
possibility of ‘active sites’ present on the lactose carrier surface. From a 
logical perspective, the reduction of ‘active sites’ by surface smoothing of 
lactose particles by controlled dissolution resulted in a significant increase in 
aerosolisation performance at lower drug concentrations. Although such 
factors may not significantly affect the majority of current inhalation 
formulations, which typically contain >100 pg of drug, the performance of 




Investigation into the influence of storage conditions 
on the delivery performance of dry powder inhalation 
formulations
5.1 Introduction
It is widely accepted that the attainment of an effective respiratory drug 
delivery is largely attributed to the interplay of physical and chemical factors 
which govern particle-particle interactions (Buckton, 1997; Zeng etal.,
2001a). The key mechanisms for the delivery of respirable particles from a 
passive DPI device is the detachment of drug particles from the surface of a 
carrier particle, dispersion of drug particles into the airflow and finally 
deposition of drug particles within the respiratory system. Thus, the 
therapeutic effect of inhaled medicaments is significantly influenced by these 
mechanisms and the physicochemical factors which govern their behaviour 
(Ganderton and Kassem, 1992; Byron etal., 1996).
As previously discussed, it is well-understood that the optimum therapeutic 
benefit of aerosol particles within the respiratory tract is the delivery of 
aerodynamic diameter particles in the size range 2 - 5 pm (Clark, 1995; 
Malcolmson and Embleton, 1998). This critical size requirement is associated 
with efficient delivery within the conducting airways rather than being lost 
through impaction and/or sedimentation in the upper airways (Prichard,
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2001). To achieve the required particle size ranges, the active ingredient is 
traditionally subjected to vigorous mechanical processing, such as 
micronisation and milling (Staniforth, 2000). The use of such high energy 
processing typically leads to production of particles with high surface free 
energies, due to the introduction of amorphous disorder, and issues relating 
to electrical charging (Buckton etal., 1988, Krycer and Hersey, 1981; Saleki- 
Gerhardt etal., 1994; Ward and Schultz, 1995; Ohta and Buckton, 2004).
As a result, the stability of a DPI formulation will be markedly threatened, 
especially if subjected to an environment displaying pronounced variations in 
temperatures and/or relative humidity (%RH) levels (Hindle and Makinen, 
1996; Price etal., 2002a). For example, thermodynamically unstable 
amorphous regions have been shown to be highly susceptible to re­
crystallisation upon exposure to elevated changes in temperature and/or 
%RH, leading to significant changes in the physicochemical properties of the 
bulk powder and the potential for irreversible particle agglomeration (Ahlneck 
and Zografi, 1990; Hancock and Zografi, 1997).
In view of the fact that inter-particulate interactions at the sub-micron scale 
are effectively a surface phenomenon, the morphology and 
crystalline/amorphous characteristics of the surface will indeed exert a 
significant influence on both the adhesive/cohesive properties of interacting 
particles and, thus, the physicochemical stability of the formulation upon 
storage at elevated temperature and %RH conditions.
For respirable sized particles, their interactions are governed by a composite 
of omni-present van der Waals forces and electrostatic and capillary forces. 
The magnitude of these physical forces is strongly influenced by particle 
properties such as particle size, shape, surface energy and surface texture 
(Podczeck, 1998a). Furthermore, the dynamic influence of the capillary and 
electrostatic forces is highly dependant on the processing and environmental 
conditions (Coelho and Hamby, 1978). Electrostatic forces, for example, 
have been shown to dominate particulate interactions at low RH levels 
.(<30% RH) (Price etal., 2002). Contact electrification arises from the contact
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and separation of two different contiguous surfaces exhibiting different 
energy states, while frictional contact between particles during powder 
mixing, handling and aerosolisation leads to triboelectrification. This force 
may be attractive or repulsive (Bailey, 1984; Peart etal., 1996). The influence 
of contact and tribology induced charging can be significantly minimised in 
the presence of moist air at reasonable levels of humidity. The condensation 
and adsorption of water onto interacting surfaces leads to an increase in 
surface conductivity, thus reducing the potential for the build-up of electric 
charge (Smeltzer etal., 1982; Rowley and Mackin, 2003). However at high 
levels of relative humidity (>65% RH), capillary forces may dominate. The 
adsorption of water onto surfaces causes attractive bonding due to the 
capillary action of the adsorbed water layers. The sorption of water is highly 
dependent on the partial water vapour pressure of the surrounding 
environment, and the hydrophilic/hydrophobic nature of the surface. 
Significant and increased condensation of water vapour will lead to the 
formation of liquid bridges via capillary action (Coelho and Harnby, 1978; 
Schubert, 1984), thus leading to a meniscus force and accordingly increased 
cohesive/adhesive behaviour between particles (Eaves and Jones, 1972).
A number of recent investigations have focussed on the influence of 
environmental conditions on inter-particulate forces, and subsequently the 
aerosolisation performance from two variant inhalation systems. The first was 
concerned with systems exhibiting drug particulates only, therefore 
concentrating on drug-drug interactions. For example, research has shown 
that the storage of a variety of micronised salbutamol salts at different 
temperature/RH levels for various time intervals (3-60 minutes), resulted in a 
relative decrease in fine particle fraction (Jashnani etal., 1995; Jashnani and 
Byron, 1996). It is very important to note, however, that the aerosolisation 
behaviour was not the same for all salts investigated. Some, for example, 
remained largely unaffected, until subjected to relatively extreme conditions, 
such as 45°C and 95% RH. Their overall conclusion highlighted that the 
stearate salt, the most hydrophobic, showed the least sensitivity to elevated 
temperature and RH levels.
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Another study (Young etal., 2003a) investigated the influence of RH on the 
aerosolisation performance of three micronised drugs, disodium 
cromoglycate (DSCG), salbutamol sulphate and triamcinolone acetonide 
(TAA). A decrease in fine particle fraction of DSCG and salbutamol sulphate 
was observed at variable levels of increased RH, suggesting that the 
particulate interactions were mainly governed by capillary forces at high 
humidity. Surprisingly, however, fine particle fraction of TAA significantly 
increased as the humidity increased over the range of 15 to 75% RH, 
suggesting that triboelectric forces were governing the particulate interactions 
at low to high humidities. Their work was further advocated through the use 
of the atomic force microscope for direct quantification of the separation 
energies between drug particulates as a function of increased RH (Young et 
al., 2003b).
For carrier based formulations, environmental conditions will unquestionably 
exert a relatively profound influence on particulate interactions and, thus, 
aerolisation performance. This is due to the large number of interactions: 
drug-drug, drug-carrier, or even carrier-carrier interactions which will be 
directly influenced by variations in temperature and/or relative humidity. A 
recent study, has investigated in vitro inhalation properties of a model drug 
from an inhalation system with surface modified lactose, compared to 
another formulation of unmodified lactose, both stored at elevated RH levels 
(lida et al., 2004a). The modified lactose was magnesium stearate processed 
lactose. The study indicated that, when tested following storage, the modified 
lactose formulation was not affected as much as the unmodified lactose 
formulation. It was suggested that the hydrophobic nature of magnesium 
stearate, thus its low susceptibility to moisture uptake, prevented the 
formation of strong capillary bridges between drug and carrier particles, 
leading to significantly weaker adhesive interactions. Braun etal. have 
undertaken a more detailed investigation into the influence of storage 
humidity on the deposition behaviour of a model drug from carrier based 
formulations with lactose excipient particles of differing particle size ranges 
and drug/carrier ratios (Braun etal., 1996). The study showed that upon 
storing at 55% RH, a decrease in fine particle fraction was observed for all
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formulations in comparision to that obtained at 33% RH. The highest fine 
particle fraction was obtained from formulations containing one to one 
drug/carrier ratio with fine carrier particles (d50 = 15.6 pm) at 41% RH. It was 
evident from such an investigation that the inhalation efficiency could be to 
some extent maintained through the appropriate selection of the excipient in 
terms of its particle size distribution and its proportion within the formulation. 
All of which however, needed to coincide with the optimum environmental 
condition at which the formulation was stored.
In a similar approach, Harjunen and co-workers studied the effect of carrier 
type, drug/carrier ratio and one month storage at 40°C, 75% RH on the in 
vitro pulmonary deposition of two model drugs. The drugs used in the study 
were budesonide (hydrophobic) and salbutamol sulphate (hydrophilic). It was 
observed that following one month storage, the fine particle fraction of 
salbutamol sulphate decreased and its behaviour was independent of the 
carrier type and drug/carrier ratio. However, the fine particle fraction of 
budesonide was found to increase when increasing drug to carrier ratio, and 
its behaviour was dependent on the carrier type (Harjunen etal., 2003). The 
increase in fine particle fraction performance of budesonide particles upon 
storage is thought to be due to the reduction of surface electrostatic 
properties (Harjunen etal., 2003). Furthermore, the increase in fine particle 
fraction of budesonide with increasingHts dose, was suggested to be related 
to the presence of ‘active sites’. When the drug concentration was low, drug 
particles would initially occupy high energy adhesion sites, thus lowering the 
chance of drug particles being detached from the surface. Whereas at higher 
doses, the probability of drug particles adhering to low energy adhesion sites 
would increase, hence facilitating more efficient particle detachment 
(Harjunen etal., 2003). It is significantly important to note, however, that such 
increase was in part correlated with the increase in drug to carrier ratio. Such 
results, for instance, seem to be contradictory at first sight to results obtained 
by a study carried out by Price et al. The outcome of this study indicated that 
capillary interactions were dominating the adhesion forces between 
budesonide and lactose particles at levels from 15 to 60% RH. It was 
suggested that such observations were possibly due to the fact that the
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unstable hydrophobic nature of the surface of budesonide particles which 
lack the presence of a saturated tightly bound water layer, rendered it more 
prone to the adsorption of thin water films which could progressively lead to 
the formation of a stable meniscus bridge (Price etal., 2002a). Further 
interesting evidence of the influence of the configuration of an inhaler 
formulation on its physicochemical stability was also significantly correlated 
with the findings of such investigations. A study carried out by Mueller-Walz 
and Keller (Mueller-Walz and Keller, patent W00028979) examined the 
impact of the addition of magnesium stearate and fine particle lactose on 
retaining short and long term stability of lactose based dry powder inhalation 
systems. In general, their study concluded that the presence of magnesium 
stearate improved the stability of formulations by exhibiting relatively minimal 
decrease in FPD and FPF following storage. On the other hand, the addition 
of fine particle lactose, although showing an initial increase in FPD and FPF 
when tested before storage, showed a dramatic decrease when tested after 
storage at the elevated temperature and RH levels.
From the discussion above, it is apparent that it is rather onerous to gain a 
definitive correlation between the strategic design of dry powder inhaler 
formulation and the maintenance of optimal aerosolisation efficiency and 
protection against the detrimental influence of environmental conditions 
during processing, packaging and storage.
In light of all this, and in order to achieve a more comprehensive insight into 
the prospective influence of environmental conditions on the performance of 
dry powder inhaler formulations, a series of stability studies were undertaken. 
Both long term and accelerated stability studies were conducted on inhaler 
formulations exhibiting different types of lactose carriers. The lactose carriers 
employed were untreated air jet sieved lactose which was most significantly 
compared to the surface etched lactose. Furthermore, fine lactose particles 
were introduced to both commercial and surface etched lactose carriers, in 
an attempt to try to gain a better understanding of the role of fine particulates 
on maintaining aerosolisation efficiency of inhalation formulations upon 
storage at elevated conditions of relative humidity.
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5.2 Materials
a-Lactose monohydrate (Lactochem® crystals) was supplied by Borculo 
Whey (Chester, UK). The lactose was vibrated through a nest of sieves to 
obtain a 63-90 pm sieve fraction, whish was used throughout the study. Air 
jet sieved lactose, which is 63-90 pm sieve fractioned commercial lactose 
that was further sieved by an air jet sieve. Sorbolac 400 lactose was supplied 
by Meggle (Wasserburg, Germany). Micronised salbutamol sulphate was 
supplied by Aventis Pharma (Cheshire, UK). HPLC grade Methanol was 
supplied by Fisher Chemicals (Loughborough, UK). Glacial acetic acid was 
supplied by BDH (Poole, UK). Ultra pure water was produced by reverse 
osmosis (MilliQ, Millipore, Molsheim, France).
5.3 Methods
General methods of each technique or apparatus used in this study are 
described in detail in Chapter 2.
5.3.1 Preparation and storage of powder formulations
Micronised salbutamol sulphate (median diameter, d50 4.79 pm) was 
geometrically blended using a Whirlymixer (Fisons Scientific Equipment, 
Loughborough, UK) at a ratio of 67.5:1 w/w with untreated air jet sieved 
lactose (AJS), 5% surface etched lactose and both with the addition of 
5%fine particle lactose (Sorbolac) within the percentage of total lactose 
considered in the blend. Blends containing fine particle lactose (Sorbolac) 
were prepared through forming an initial blend of coarse and fine lactose 
utilising the same method described in Chapter 2. This blend was then 
further mixed with micronised salbutamol sulphate to obtain the final blend.
117
Upon geometric mixing, blends were placed in a Turbula and mixed at 46 
rev.min'1 for 30 minutes. All blends were initially stored in a controlled 
environment of 44% RH for at least 24 hours before conducting content 
uniformity measurements.
Content uniformity was investigated by analysing 30.0 ± 2 mg samples 
(n=10) of each blend. Sample analysis was conducted using high 
performance liquid chromatography. Content uniformity of all blends gave a 
relative standard deviation of less than 5%. Hard gelatin capsules (Size 3) 
were filled with 30.0 ± 2 mg of each powder blend. Filled capsules were then 
divided into four batches for further in vitro performance investigations using 
the multi stage liquid impinger (MSLI).
One of batches was stored at ambient conditions, 44% RH at 25°C, prior to in 
vitro investigations. The constant humidity level was obtained by the use of a 
saturated salt solution of potassium carbonate which was placed in a tightly 
sealed container with the formulated blend (O’Brien, 1948).
Two batches were stored at 75% RH at 25°C for one and three months. The 
75% RH level was obtained by the use of the saturated salt solution of 
sodium chloride placed in a tightly sealed container (O’Brien, 1948). The final 
batch was stored at 75% RH at 40°C for one month. These conditions were 
obtained by the use of the saturated salt solution of sodium chloride placed in 
a tightly sealed container, which was stored in a 40°C temperature controlled 
oven (O’Brien, 1948).
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5.3.2 Drug content determination
Quantification of salbutamol sulphate content uniformity and in-vitro 
deposition was carried out by high performance liquid chromatography 
(HPLC). The HPLC system consisted of an AS950 intelligent sampler, PU- 
980 intelligent HPLC pump, 975 UV/VIS detector (all Jasco, Japan) and 
Spherisorb 15 cm, 5 pm ODS1 column (Waters, Milford, MA, USA).
The mobile phase used throughout the investigation was methanol/water 
(60:40) and acetic acid 0.1 % v/v. Settings were as follows: detection 
wavelength 276 nm; flow rate 1.25 ml.min"1; pressure approximately 400 
Kg.m2; injection volume 100 pi; analysis time 4 min; approximate retention 
time 2 min.
Linearity was confirmed between 0.1 and 10 pg.ml'1 (R2 = 0.99). Lactose did 
not interfere with the salbutamol sulphate response. Sample injections were 
performed in duplicate using a bracket standard method containing standards 
prepared from separate stock solutions.
5.3.3 Dynamic vapour sorption
Moisture sorption profiles of the untreated air jet sieved lactose (AJS) and 
surface etched lactose were determined by dynamic vapour sorption (DVS) 
(DVS-1, Surface Measurement Systems, London, UK). Approximately 50 mg 
of powder sample was weighed into the sample pan of the DVS and exposed 
to a 0-90% RH cycle, at 10% RH increments. Equilibration moisture content, 
at each humidity, was determined with a dm/df of 0.0002% min*1.
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5.3.4 In vitro aerosolisation studies
The pulmonary deposition of salbutamol sulphate was assessed by the use 
of a multi stage liquid impinger (MSLI) (Copley Instruments Ltd., Nottingham, 
UK). The MSLI apparatus consists of a throat, four classifying stages into 
which 20 ml of the HPLC mobile phase are introduced, and a fifth dismantled 
stage on top of which a fiber glass filter is placed. Upon achieving an air tight 
seal, single capsules containing the nominal dose of 400 ± 30 pg of 
salbutamol sulphate were actuated via a Cyclohaler® (Novartis, Surrey, UK) 
at 60 L.min'1 for 5 seconds. The device is specifically fitted with a moulded 
rubber mouthpiece for attachment to the throat piece of the liquid impinger. 
The flow rate was adjusted using a rotary vein pump and solenoid-valve 
(Copley Scientific Ltd., Nottingham, UK) and calibrated using a reference flow 
meter. The pump was allowed to run for 4 seconds prior to and post 
solenoid-valve actuation, to allow the pump time to settle. The concentration 
of drug in each stage was determined by rinsing with mobile phase both the 
inner wall and the collection disc of the corresponding stage, followed by 
tilting and rotating the apparatus. The device, metal throat and the filter were 
also washed for drug extraction. The cut-off mass median aerodynamic 
diameters were 13.0, 6.8, 3.1 and 1.7 pm for stages 1, 2, 3 and 4, 
respectively, at 60 L.min'1. The aerosolisation characteristics were described 
as: loaded dose (LD) which represents drug recovered from the device, 
mouthpiece, throat and all stages of the MSLI; emitted dose (ED) which 
represents drug emitted from the device into the mouthpiece, throat and all 
stages of the MSLI; fine particle dose (FPD) which represents drug deposited 
on stages 3, 4 and 5 (effective cut-off diameter < 6.4 pm); fine particle 
fraction (FPF) which represents the percentage of FPD to LD.
5.3.5 Optical imaging of powder samples
Digital optical images of samples of powder blends were taken immediately 
after each formulation was emptied from representative capsules that were
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stored for the specified time periods at the various environmental conditions 
investigated throughout the study.
5.4 Results and discussion
5.4.1 Physical characterisation
To achieve a comprehensive understanding of the influence of environmental 
storage conditions on formulation stability and performance, the deposition 
behaviour the DPI formulations and physical characterisation of the various 
lactose carriers was initially conducted. Lactose samples were characterised 
via their particle morphology, particle size and moisture sorption 
characteristics.
Representative scanning electron photomicrographs of air jet sieved lactose, 
surface etched lactose, air jet sieved lactose with fines and surface etched 
lactose with fines are shown in Figure 5.1. As previously discussed, the 
images clearly display the influence of the novel surface etching process on 
the surface roughness and the reduction in the level of intrinsic fines. Particle 
morphology investigations were also conducted on samples of lactose 
carriers, with and without added fines, upon storage at 40°C, 75% RH for one 
month as shown in Figure 5.2. On an individual particle level, there were no 
apparent differences for both air jet sieved and surface etched lactose 
samples with and without fines.
The cumulative undersize distribution of the four lactose carriers examined is 
graphically represented in Figure 5.3. The surface etching process resulted in 
removal of approximately 90% of fine lactose particles (quantified with 
regards to the percentage of particles exhibiting a diameter of less than 5 
pm), when comparing the surface etched lactose with the untreated air jet 
sieved lactose. Surface etched lactose was found to have a median particle 
diameter of 99.54 pm with only 2.5% of particles having a diameter of less
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than 5 pm. On the other hand, air jet sieved lactose with fines was found to 
have a median particle diameter of 15.85 pm with approximately 29% of 
particles having a diameter of less than 5 pm. In addition, surface etched 
lactose presented a volume median diameter (VMD) of about 112 pm, which 
was the highest among the lactose carriers examined in this study. Such 
findings indeed emphasise again on the dependence of apparent particle 
descriptors, and the fact that air jet sieving, for example, could not be 
considered as an efficient dependable method utilised for the removal of fine 
particulates. As a consequence, possible inter and intra batch variations may 
occur for such particles, thus giving rise to potential implications in terms of 
formulation performance.
Figure 5.1. Representative SEM images of air jet sieved lactose (A), air jet 
sieved lactose with fines (B), surface etched lactose (C) and surface etched 
lactose with fines (D).
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Figure 5.2. Representative SEM images of air jet sieved lactose (A), air jet 
sieved lactose with fines (B), surface etched lactose (C) and surface etched 
lactose with fines (D). The SEM images of lactose samples were taken 
following one month storage at 40°C, 75% RH.
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Figure 5.3. Cumulative undersize distribution graph of air jet sieved lactose, 
air jet sieved lactose with fines, surface etched lactose and surface etched 
lactose with fines.
Sorption isotherms, determined as percentage of dry mass, for untreated air 
jet sieved lactose and surface etched lactose samples are shown in Figure 
5.4. All DVS experiments were conducted at 259C. The sorption isotherms 
clearly suggest that at low relative humidity levels (0-50% RH) both surface 
etched lactose and untreated air jet sieved lactose samples demonstrated a 
similar adsorption profile. However, above 50% RH increasing relative 
humidity led to a noticeable difference in their water adsorption behaviour. At 
75% RH, for example, there was about 2.5 fold increase in the moisture 
sorption profile of air jet sieved lactose when compared to surface etched 
lactose. This difference increased with further increase in %RH. At 90% RH 
the difference was over 3 fold. A possible and logical explanation to such 
observations is that the surface of the untreated lactose particle may exhibit 
high surface free energy sites due to surface irregularities and/or increased 
sorption propensity at high levels of %RH associated with amorphous 
disorder related to the powder processing conditions of the lactose.
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Meanwhile, the surface passifying effects of the temperature controlled 
surface etching process, may reduce the degree of reactive “hot spots” for 
moisture sorption, thereby leading to a decrease in the equilibration sorption 
of moisture at elevated conditions of relative humidity. This may be achieved 
by a possible reduction in the degree of high surface energy sites available 
for moisture condensation and the possible reduction in the degree of 
amorphous disorder, which is well-known to increase the degree of moisture 
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Figure 5.4. Effect of increasing relative humidity on the DVS isotherms of air 
jet sieved and surface etched a-lactose monohydrate samples.
5.4.2 In vitro aerosolisation studies
The fine particle delivery efficiency of salbutamol sulphate from the prepared 
blends of air jet sieved lactose, air jet sieved lactose with fines and surface 
etched lactose and surface etched lactose with fines as a function of varying 
accelerated stability conditions are shown in Figures 5.5 and 5.6,
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respectively. The aerosolisation performance of the formulations, which were 
calculated in terms of fine particle dose (FPD) and fine particle fraction (FPF), 
are also tabulated in Tables 5.1 and 5.2, respectively. Figure 5.5 shows the 
comparison in FPF for the prepared formulations upon storage at 25°C, 75% 
RH for one and three months with respect to a control, which was conducted 
at ambient conditions (25°C, 44%RH). Figure 5.6 shows the comparison of 
FPF performance of the formulations upon storage at 40°C, 75% RH for a 
month, with respect to the control at ambient conditions.
When comparing the performance of the control blends, there is no 
significant difference in the aerosolisation efficiency of the model drug from 
air jet sieved lactose, air jet sieved lactose with fines and surface etched 
lactose blends (P > 0.05). However, a dramatic increase (approximately 
90%) in the delivery performance of the drug from surface etched lactose 
was achieved upon the introduction of 5% fine lactose.
Interestingly, however, the fine particle delivery performance of the blends 
varied significantly upon storage at 25°C, 75% RH for one month. A 
significant decrease in the FPF performance was observed with both air jet 
sieved lactose (p < 0.001) and air jet sieved lactose with fines (p < 0.05) 
when compared to their control values at ambient conditions. On the 
contrary, there was no significant difference in FPF of drug delivered from 
surface etched lactose when compared to its control value upon storage at 
25°C, 75% RH for one month. The most significant decrease in FPF of the 
drug (p < 0.001) was obtained from the surface etched lactose with fines 
blend, exhibiting a decrease in FPF of approximately 67% with respect to its 
control value. This significant drop in FPF of surface etched lactose with fines 
blend was not only seen in this particular storage condition, but also upon 
storage at 25°C, 75% RH for three months and upon storage at 40°C,
75%RH for a month. Fisher’s pairwise comparison of the ANOVA data for 
surface etched lactose with fines found significant differences in FPF upon 
three months storage at 25°C, 75% RH (p < 0.001) with a 67% decrease in 
FPF (Figure 5.5), and also upon one month storage at 40°C, 75% RH (p < 
0.01), with a 55% decrease in FPF (Figure 5.6).
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In a similar manner to its behaviour at 25°C, 75% RH for one month, surface 
etched lactose showed no significant difference in delivery performance upon 
storing the formulation at 25°C, 75% RH for three months (Figure 5.5). 
Furthemore, no significant differences were observed upon storage at 40°C, 
75% RH for one month (Figure 5.6). These data indicated that the delivery 
performance of the drug from surface etched lactose was to some extent 
maintained despite the exposure of the formulation to elevated conditions of 
temperature and relative humidity.
Meanwhile, air jet sieved lactose (p < 0.001) and air jet sieved lactose with 
fines (p < 0.01) blends exhibited a significant decrease in FPF upon storing 
the formulations at 25°C, 75% RH for three months with approximately 75% 
and 79% decrease in FPF, respectively. Interestingly, although the FPF of 
the air jet sieved lactose and air jet sieved lactose with fines decreased upon 
exposure to 40°C, 75% RH for one month, the decrease was not as 
significant as upon exposure to 25°C, 75% RH for three months (Figure 5.6).
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Figure 5.5. Effect of one and three months storage of powder blends at 25°C, 
75% RH on fine particle fraction in comparison to control conditions. (*p < 
0.05, **p< 0.01, ***p <0.001 confidence of variation by Fisher’s pairwise 
comparisons).
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Figure 5.6. Effect of one month storage of powder blends at 40°C, 75% RH 
on fine particle fraction in comparison to control conditions. (*p < 0.05, **p < 
0.01, ***p< 0.001 confidence of variation by Fisher’s pairwise comparisons).
More detailed graphical description of the percent to loaded dose of 
salbutamol sulphate deposited of all formulations on each stage of the MSLI 
apparatus for the control (25°C, 44% RH), 25°C, 75% RH for one month, 
25°C, 75% RH for three months and 40°C, 75% RH for one month are shown 
in Figures 5.7, 5.8, 5.9 and 5.10, respectively. For control conditions, surface 
etched lactose with fines demonstrated the lowest deposition of drug at 
throat+stagel, and the highest deposition at stages 3 and 4. It is important to 
note, however, that at the throat+stagel level, the deposition of drug from 
surface etched lactose formulation was less than that observed with air jet 
sieved lactose and air jet sieved lactose with fines formulations. When 
examining the deposition profile of salbutamol sulphate following storage 
under accelerated stability conditions (Figures 5.8, 5.9 and 5.10), surface 
etched lactose displayed the lowest percent drug deposited at the 
throat+stagel level, implying that a higher percent of drug particulates 
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Figure 5.7. Percentage drug deposition to loaded dose on the MSLI stages at 
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Figure 5.8. Effect of one month storage at 25°C, 75% relative humidity on the 
percentage drug deposition to loaded dose on the MSLI stages from the 
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Figure 5.9. Effect of three months storage at 25°C, 75% relative humidity on 
the percentage drug deposition to loaded dose on the MSLI stages from the 
lactose formulations under examination.
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Figure 5.10. Effect of one month storage at 40°C, 75% relative humidity on 
the percentage drug deposition to loaded dose on the MSLI stages from the 
lactose formulations under examination.
130
Carrier FPD(m)
Control 25°C/75%RH 1M 25°C/75%RH3M 40°C/75%RH 1M
Air jet sieved lactose (AJS) 44.7 ±1 .9 9.7 ±0 .8 7.6 ± 3 .9 24.2 ± 3.9
AJS + fines 45.9 ±1 .3 15.5 ±7 .8 5.2 ± 5.6 34.4 ± 5.4
Surface etched lactose 37.0 ± 8.4 19.6 ±2 .5 20.7 ±  9.4 33.4 ±  3.0
Surface etched + fines 80.5 ±21.9 19.9 ±1.1 17.3 ±5.1 34.8 ±  7.6
Table 5.1. Influence of environmental storage condition on fine particle dose
of salbutamol sulphate (mean ± S.D. are shown; n=3).
Carrier FPF (%)
Control 25°C/75%RH 1M 25°C/75%RH 3M 40°C/75%RH 1M
Air jet sieved lactose (AJS) 10.3 ±0 .3 3.5 ± 0.3 2.5 ±1 .3 6.1 ±1 .0
AJS + fines 9.7 ± 0.5 4.8 ± 2.7 2.0 ±  2.2 8.0 ±1 .3
Surface etched lactose 9.8 ±1 .9 6.8 ± 0.8 7.6 ±2 .7 9.1 ±0 .5
Surface etched + fines 18.6 ±2.1 6.2 ±0.1 6.1 ±2.1 8.3 ±1 .8
Table 5.2. Influence of environmental storage condition on fine particle 
fraction of salbutamol sulphate (mean ± S.D. are shown; n=3).
To further probe the potential mechanism for the decrease in performance 
upon storage at conditions of elevated temperature and relative humidity, the 
potential for caking of the prepared formulations were examined via optical 
imaging. Optical images were taken immediately after releasing the powder 
blends from the capsules that were stored at the various storage conditions. 
Optical images of the blends released from capsules stored for one month at 
25°C, 75% RH, three months at 25°C, 75% RH and one month at 40°C, 75% 
RH are shown in Figures 5.11, 5.12 and 5.13, respectively. In contrast to the 
microscopic analysis of individual particles with the SEM, macroscopic scale 
images of the powder formulation indicated the possible mechanism of failure 
of the carrier based formulations upon exposure to accelerated stability 
conditions. The optical images showed that for all environmental storage
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conditions, air jet sieved lactose, air jet sieved lactose with fines and surface 
etched lactose with fines underwent considerable degree of powder 
clustering (agglomeration). However, such powder aggregation was not 
observed with the surface etched lactose particle blend. Such physical 
bonding and crystal agglomeration may be an indication of a considerable 
increase in inter-particle adhesion due to capillary interaction, arising from 
the condensation of the increasingly adsorbed water vapour layers onto the 
surface of crystals at high RH levels, as a consequence, promoting the 
formation of a capillary meniscus around the contact points of contiguous 
surfaces.
Another possible source of particle surface instability is thought to be the 
presence of amorphous domains which are liable to re-crystallisation at 
conditions of elevated RH levels (Briggner etal., 1994; Buckton and Darcy,
1995) leading to solid crystal bridging.
Lactose crystals processed via the temperature controlled surface etching 
technique were likely to exhibit reduced amorphous content and passivated 
highly energetic surface sites. This maybe indicated by the decrease in the 
amount of water vapour adsorbed onto the surface at high RH levels. This 
led to no apparent powder agglomeration of the temperature controlled 
surface etched lactose formulations.
Another point to consider is that the addition of fine lactose particles may 
exacerbate the instability of carrier based formulations when subjected to 
environmental conditions of elevated temperature and relative humidity. This 
may be in part attributable to a potential increase in the overall surface area 
available for water vapour adsorption. Moreover, as a result of the high 
energy processing of fine carrier particulates, they are also more likely to 
show evidence of crystalline disorder, demonstrating a proportion of 
amorphous regions that would further enhance solid crystal bridging due to 
re-crystallisation at conditions of elevated temperature and humidity.
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As previously discussed, while the introduction of a specified percentage of 
fine lactose particulates to surface etched lactose formulations demonstrated 
a striking increase in delivery performance at control conditions, such 
performance was markedly decreased following storage at all the tested 
environmental conditions. Thus, the enhanced delivery performance 
achieved upon the addition of fines could not be maintained as function of 
accelerated stability testing. A considerable 67% decrease in the 
aerosolisation efficiency was observed upon storing surface etched lactose 
with fines formulation at 25°C, 75% RH for one and three months. Moreover, 
a 55% drop in FPF was also noticeable when surface etched lactose with 
fines formulations was exposed to a condition of 40°C, 75% RH for one 
month. Moreover, surface etched lactose formulations showed a 30% 
decrease in FPF performance when stored for one month at 25°C, 75% RH, 
a 22% decrease in FPF performance when stored for three months at 25°C, 
75% RH and finally a 7% decrease in FPF performance when stored for one 
month at 40°C, 75% RH. Such observations clearly indicate that the surface 
etched lactose formulation was indeed the least formulation to be affected by 
the exposure to the various environmental conditions in spite of the fact that it 
did not yield the highest FPF value upon aerosolisation at control conditions. 
The results obtained from this study emphasise the critical significance of 
conducting long-term and accelerated stability studies when considering the 
implementation of crucial modifications to a DPI formulation. Therefore, 
ensuring that enhanced performance at control conditions would be to some 
extent maintained in terms of powder homogeneity and reproducibility even 
upon exposure to rather extreme environmental conditions.
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Figure 5.11. Optical images of air jet sieved lactose (A), air jet sieved lactose 
with fines (B), surface etched lactose (C) and surface etched lactose with 
fines (D). Images indicate the influence of increased RH on the behaviour of 
powders released from capsules stored for one month at 25QC, 75% RH.
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Figure 5.12. Optical images of air jet sieved lactose (A), air jet sieved lactose 
with fines (B), surface etched lactose (C) and surface etched lactose with 
fines (D). Images indicate the influence of increased RH on the behaviour of 
powders released from capsules stored for three months at 25QC, 75% RH.
Figure 5.13. Optical images of air jet sieved lactose (A), air jet sieved lactose 
with fines (B), surface etched lactose (C) and surface etched lactose with 
fines (D). Images indicate the influence of increased temperature and RH on 
the behaviour of powders released from capsules stored for one month at 
409C, 75% RH.
As previously discussed, the interplay of a number of factors may possibly 
give rise to an increase in the interaction force between particles when 
subjected to elevated temperature and RH levels. Such crucial elements 
could be the presence of thermodynamically unstable sites that are usually in 
the form of interchangeable crystalline/amorphous domains. Moreover, the 
inconsistency in surface roughness of untreated mechanically processed 
carrier particles, may be the source for increased water sorption leading to 
increased particle-particle interactions.
In view of all this, the novel temperature controlled surface etching process of 
commercial grade a-lactose monohydrate particles may indeed be perceived 
as a valuable approach towards the surface conditioning of the rather 
unstable industrially processed carrier particles. Such surface conditioning
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involves a possible elimination of particle irregularities, alleviation of surface 
amorphous regions, optimisation of surface roughness. Thus, allowing the 
production of carriers which exhibit improved batch to batch consistency. 
Further, the conditioning of the lactose particle surface has been shown to 
possibly enhance the physicochemical stability of dry powder inhaler 
formulations at extreme environmental conditions.
Another key element to take into consideration, is the possible physical 
instability arising from the introduction of fine particulates. Such instability 
was markedly profound particularly following the exposure of fines-containing 
formulations to the intense environmental conditions.
The possible role that fine carrier particulates play in issues related to the 
stability and possible loss in performance of a carrier based dry powder 
inhaler formulation has not been fully understood. Investigations relating to 
the use of fines, has mainly been focussed on the fundamental 
understanding of the influence of fines on the increased aerosolisation 
performance of dry powder inhaler formulations upon processing. A number 
of theories have been employed in order to explore the exact mechanisms by 
which they are thought to enhance the aerosolisation performance. A logical 
explanation that could be predicted is the they preferentially occupy highly 
energetic ‘active site’, thus leaving the low adhesion ‘active sites’ more 
available from drug particulates. It is without doubt, however, that one of the 
most significant outcomes of this part of the study, is that it highlighted the 
potential ‘negative’ influence of fine carrier particulates in the long term 
stability of the formulation. This study has clearly emphasised the need to 
understand long term stability issues and to combine the influence of all 
interacting factors under a broad fundamental insight of the means to achieve 
and maintain aerosolisation performance.
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5.5 Conclusions
Variations in temperature and RH levels of the surrounding environment of a 
carrier based DPI formulation was found to markedly influence its pulmonary 
delivery performance. Significant variations in the fine particle dose and fine 
particle fraction were obtained as a function of storage at various 
atmospheric conditions. The study indicated that the use of surface etched a- 
lactose monohydrate particles maintained efficient pulmonary drug delivery 
following exposure to elevated environmental conditions. The study 
suggested that surface roughness variations of carrier particles may strongly 
be a possible source of inter and intra batch inconsistency therefore more 
profound physicochemical instability of formulations. Additionally, the stability 
of formulations demonstrating a higher percentage of fine carrier particulates 
was significantly threatened, suggesting the significance for further studies to 
be conducted as to the assessment of the role of intrinsic and extrinsic fines 





The efficient development of a dry powder inhalation system in yielding an 
effective pulmonary delivery is critically dependent on the interplay of a 
myriad of crucial determinants. However, the key factors affecting de­
agglomeration and aerosolisation of respirable particles may possibly be 
reflected by two main competing physical aspects. These are the inter­
particulate forces acting between contiguous particles surfaces and the long 
term physicochemical stability of DPI formulations upon storing and handling 
at various environmental conditions of temperature and humidity. It is also 
significant to note however, that the effect of these two elements relates to 
the aerodynamic forces created by the inspiratory air flow applied by the 
patient, promoting the fluidisation and de-agglomeration of the respirable 
particles. Thus, it is logical that a prediction and to some extent a control of 
the physicochemical determinants is thought to be of uppermost significance 
in the attempt of gaining a more comprehensive understanding of the 




The primary aim of this study was to develop a novel surface etching method 
that would enable controlled modification of the nanometer scale surface 
characteristics of excipient particles. An apparent and direct correlation was 
further established between the qualitative characterisation of the surface 
morphology of etched lactose excipient particles and the quantitative in vitro 
deposition profile of the respirable fraction of the model drug salbutamol 
sulphate that was employed throughout the study.
Preliminary findings suggested the existence of an apparent relationship 
between the surface topography of excipient particles in terms of roughness 
and the aerosolisation performance of salbutamol sulphate. The efficient 
delivery of the respirable fraction of the drug was found to be significantly 
improved upon decreasing the surface roughness of lactose carrier particles. 
Nonetheless, the study also clearly indicated a proposed manipulation of 
drug-carrier inter-particulate interactions as a function of increased degree of 
surface etching. That is to say, optimisation of surface etching is an essential 
requirement for maintaining most advantageous cohesive/adhesive 
characteristics that would ensure both reproducibility and long term stability 
of the DPI formulation.
Moreover, one of the most significant outcomes of the novel temperature 
controlled surface etching process besides modifying the surface roughness 
of excipient particles, is the possible attainment of inter and intra batch 
consistency. Such cross-batch equivalency may possibly be regarded as one 
of the imperative determinants influencing formulation performance. Such 
equivalency resides in the concept of obtaining consistent and dependable 
removal of intrinsic fine particle content and controllable modification of 
surface roughness.
Surface etched lactose particles were found to relatively improve the 
respirable fraction of tested DPI formulations for low drug doses. These 
findings suggested that surface etching of lactose particles may have
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resulted in a considerable decrease of ‘active sites’, thus reducing the 
fraction of the dose utilised solely to passify the ‘active sites’. As a 
consequence, the remaining unbound fraction, which is more prone to 
adhering to the lower energy ‘passive sites’ may increase the delivery 
efficiency. With regards to surface etched lactose particles, the saturation 
level of active sites maybe reached with a significantly lower dose in 
comparison to untreated commercial grade and air jet sieved lactose 
particles.
A parallel investigation was also carried out as part of an attempt to study the 
influence of environmental conditions on dry powder formulation delivery 
characteristics. A series of both long term and accelerated stability studies 
were performed. Dry powder formulations exhibiting surface etched lactose 
and untreated air jet sieved lactose were subjected to various storage 
conditions. Furthermore, a defined percent of fine lactose carrier particulates 
was introduced to both surface etched and untreated air jet sieved lactose 
particles, and such formulations were also subjected to the same storage 
conditions. Initial investigations conducted at control conditions indicated an 
apparent and noticeable increase in delivery performance which was clearly 
demonstrated by surface etched lactose upon the introduction of fine carrier 
particulates. This was not the case, however, following the storage of tested 
formulations at the various environmental conditions. The highest drop in fine 
particle delivery performance was obtained from the surface etched lactose 
with fines blend at all tested environmental conditions. Air jet sieved lactose 
and air jet sieved lactose with fines also exhibited evident variations in their 
delivery performance upon exposure to rather sever conditions of elevated 
temperature and relative humidity (RH) levels. Conversely however, the 
delivery performance of the drug from surface etched lactose formulations 
was significantly more stable despite the exposure of formulations to the 
elevated temperature and RH levels at all the designated environmental 
storage conditions. Such findings emphasise on the surface instability that 
was introduced upon the addition of fine carrier particulates. The study also 
highlighted that more profound physicochemical instability is strongly related
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to the surface roughness variations and particle irregularities that are 
perceived as cross-batch inconsistencies. Moreover, the study also indicated 
that optimal environmental conditions during processing, handling and 
storage of DPI formulations are indeed a necessity towards achieving the 
desired delicate balance of inter-particulate interactions.
Overall one can predict that the novel temperature controlled surface etching 
process may indeed offer a plausible approach towards alleviating 
unfavourable shortcomings that may possibly be related to various excipient 
batch discrepancies. This in turn would possibly enhance and to some extent 
maintain the efficiency of pulmonary drug delivery of dry powder inhaler 
formulations, thus establishing the solid basis for the future perception of 
further improvements that are yet to be achieved in the field of dry powder 
inhalation pharmaceuticals.
6.3 Suggested future work
As a result of this research study the use of a novel temperature controlled 
surface etching technique for modifying the surface physicochemical 
properties of commercial grade lactose has been shown to provide a better 
methodology for further investigations to be carried out with the goal of 
presenting a more comprehensive understanding of the quantification of 
surface characteristics of excipient particles and their direct correlation to 
inter-particulate forces governing the behaviour of aerosolised powders.
Notwithstanding, the novel temperature controlled surface etching process 
has been so far only applied on a-lactose monohydrate carrier particles. 
Further investigations into its applicability to other various excipient particles 
may indeed be taken into consideration. Another interesting field of study that 
might be of significant importance is the possibility of subjecting fine carrier 
particulates to the surface etching process, therefore investigating the
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controlled adjustment of the critical etching parameters in order to render it 
applicable to lower particle size distributions.
Extended effort may also be undertaken in order to gain a more valuable 
insight into the ambiguous role of fine carrier particulates on aerosolisation 
behaviour. Moreover, such investigations are more preferably to be 
conducted concomitantly with more extensive long term stability studies. For 
example, surface etched fine carrier particulates might offer a more plausible 
solution for the attainment of long term efficiency and reproducibility of 
powder formulations despite the various intense storage conditions, all of 
which are yet to be explored.
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